Contents lists available at ScienceDirect



Translational Oncology



journal homepage: www.elsevier.com/locate/tranon

Development and validation of a nomogram to predict overall survival of T1 esophageal squamous cell carcinoma patients with lymph node metastasis



Jia Yu, Wenyu Hu, Nan Yao, Mengzi Sun, Xiaotong Li, Ling Wang, Yixue Yang, Bo Li*

Department of Epidemiology and Biostatistics, Jilin University School of Public Health, 1163 Xinmin Street, Changchun, Jilin, 130021, China

ARTICLE INFO

Keywords: Esophageal squamous cell carcinoma Lymph node metastases Overall survival Prognosis Nomogram

ABSTRACT

Purpose: To develop a nomogram for predicting the prognosis of T1 esophageal squamous cell carcinoma (ESCC) patients with positive lymph node.

Methods: T1 ESCC patients with lymph node metastasis diagnosed between 2010 and 2015 were selected from the Surveillance, Epidemiology, and Final Results (SEER) database. The entire cohort was randomly divided in the ratio of 7:3 into a training group (n=457) and validation group (n=192), respectively. Prognostic factors were identified by univariate and multivariate Cox regression models. Harrell's concordance index (C-index), receiver operating characteristic (ROC) curve, and calibration curve were used to evaluate the discrimination and calibration of the nomogram. The accuracy and clinical net benefit of the nomogram compared with the 7th AJCC staging system were evaluated using net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA).

Results: The nomogram consisted of eight factors: insurance, T stage, summary stage, primary site, radiation code, chemotherapy, surgery, and radiation sequence with surgery. In the training and validation cohorts, the AUCs exceeded 0.700, and the C-index scores were 0.749 and 0.751, respectively, indicating that the nomogram had good discrimination. The consistency between the survival probability predicted by the nomogram and the actual observed probability was indicated by the calibration curve in the training and validation cohorts. For NRI>0 and IDI>0, the predictive power of the nomogram was more accurate than that of the 7th AJCC staging system. Furthermore, the DCA curve indicated that the nomogram achieved better clinical utility than the traditional system.

Conclusions: Unlike the 7th AJCC staging system, the developed and validated nomogram can help clinical staff to more accurately, personally and comprehensively predict the 1-year and 3-year OS probability of T1 ESCC patients with lymph node metastasis.

Introduction

Esophageal cancer (EC) is the 7th most common cancer and the 6th leading cause of cancer deaths worldwide [1]. Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of the 456,000 cases of esophageal cancers per year [2], and its prognosis remains poor. The causes of poor prognosis might be related to the main characteristics of ESCC, including extensive lymph node networks, early regional tumor progression, and early regional lymph node metastases (LNM) [3-5]. For ESCC patients with LNM, the greater number the metastatic lymph nodes, the worse was the prognosis [6,7]. Cancer patients can show favorable survival performance if they are identified at an early stage; for example, the 5-year survival rate of non-small cell lung cancer

patients with surgical resection at 0-I stage is 70%, and the 5-year survival rate for ovarian cancer patients diagnosed at stage I is 92% [8,9]. In recent decades, early esophageal cancer with LNM can be detected by endoscopy [10]. However, despite early detection and complete resection, the 5-year survival rate for patients is only 40% to 50%, and the prognosis remains unsatisfactory [11]. It is therefore important to find prognostic evidence for ESCC patients with LNM at the early stage.

The most common cancer-related prognosis assessment system is the American Joint Committee on Cancer (AJCC) staging system, which has been serving as a valuation system in the United States since 1959. This system classifies the extent of cancer based primarily on anatomical information of the extent of the primary tumor, regional lymph nodes, and distant metastases. However, it has disadvantages in predicting the

* Corresponding author.

E-mail address: li_bo@jlu.edu.cn (B. Li).

https://doi.org/10.1016/j.tranon.2021.101127

Received 24 January 2021; Received in revised form 13 May 2021; Accepted 13 May 2021

1936-5233/© 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

prognosis of cancer because it does not consider certain personal factors such as demographics, number of tumors, and clinical treatments. Hence, even patients at the same cancer stage display different progress and survival times. Therefore, a comprehensive and personalized model for prediction should be developed for patients diagnosed with some cancers. For the past few years, nomograms have been applied to predict the prognosis of cancer [12]. Nomograms meet the requirements for an integrated model that includes clinical and demographical variables, and thus play an essential part in driving toward individualizedand comprehensive-related factor evaluation model [13,14]. To date, no nomogram has been constructed to predict risk factors related to prognosis in T1 ESCC patients with positive lymph nodes. In the present study, by using the ESCC cohort of the Surveillance, Epidemiology and End Results (SEER) database, we aimed to identify prognostic factors for patients with ESCC and construct a prognostic nomogram model for these targeted populations.

Materials and methods

Data source

obtained SEER The data were from the database (https://seer.cancer.gov), which is a comprehensive source of population-based cancer-related information from collaboration between the US Centers for Disease Control and Prevention, the National Cancer Institute, and regional and state cancer registries. The specific dataset with chemotherapy and radiotherapy applied in the present study was the "SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub 1975-2016". Study data was screened using SEER*Stat software (version 8.3.5) provided by the SEER database.

Patient selection

Patients diagnosed with EC were initially recovered from the SEER database for the period between January 1975 and November 2016. The data were then filtered using the Code of International Classification of Diseases, 3th edition (ICD-O-3) defined as 8070-8076; the stage of tumor infiltration was T1, the number of metastatic lymph nodes was greater than 0, and survival status as well as vital status were clear.

Variable selection

Variables for the nomogram, included demographic information, pathological features, and clinical treatments. For demographic data, age at diagnosis, race, sex, insurance, rural-urban continuum, marital status, and follow-up time were selected. For pathological features, primary sites, summary stage, AJCC stage, T stage, N stage, M stage, grade, CS extension, number of malignant tumors as well as benign tumors were included. For clinical treatments, surgery status, radiotherapy status, and chemotherapy status were included in this study. The primary outcomes were the vital status and survival months.

According to the 7th AJCC staging system, seven variables are used for the evaluation of EC and include the depth of infiltration of the tumor (T), number of metastatic lymph nodes (N), distant metastases (M), histopathological type, biological activity of the tumor (histological grade), histological stage (AJCC Stage), and location. In the present study, only one subtype of EC-ESCC patient was used for the study population, the histopathological type was not entered into the AJCC staging system as a variable. The final variables that were applied for the AJCC staging system were TNM stage, histological grade, AJCC stage, and location.

Statistical analysis

All patients were randomly divided into a training and validation group. Frequencies and percentages were described as class variables. A chi-square test was used to compare categorical variables and Student's t-test to continuous variables. Cox regression analyses were used to identify factors that may affect OS. A nomogram to predict 1- and 3-year overall survival (OS) probabilities was developed by applying variables from Cox multivariate regression analyses. After the model was established, several indicators were used to validate the model. The concordance index (C-index) and the receiver operating characteristic (ROC) curves with area under the curve (AUC) were used to evaluate the discrimination capability of model. C-index and AUC ranged from 0.5 to 1.0. Basically, C-index and AUC over 0.7 indicate that the nomogram provides a reasonable estimation. Calibration plots were applied to assess the uniformity between the actual outcomes and the predicted probabilities. The net reclassification index (NRI) quantifies how well a new model reclassifies subjects as compared to an old model, while the integrated discrimination improvement index (IDI) considers different tangent lines that can be used to assess the overall improvement of the model. These two indicators can be used to evaluate the improved or decreased accuracy of a new model compared to the 7th AJCC staging system. Formally, a NRI>0 indicates the new model is more accurate than the old model for prediction. To the same is true for IDI. Finally, decision-curve analysis (DCA) was used to evaluate the clinical validity of the nomogram by quantifying the net benefit compared to the 7th AJCC staging system.

Statistical analysis was conducted using R software (version 4.0.3, https://www.r-project.org/). In the present study, the R packages used in the study included doBy, plotrix, stringi, stringr, nnet, car, mgcv, gdata, caret, rms, survival, rms, foreign, survival, ROC, and nricens packages. *p*-values were derived from two-tailed tests, and a p < 0.05 was considered statistically significant.

Results

Baseline characteristics of patients

Data on 649 T1 ESCC patients diagnosed with positive lymph nodes from 2010 to 2015 were extracted from the SEER database and then randomly divided into a training set and validation set in a 7:3 ratio. The average age of the patients was 68.17 ± 11.25 years. The majority of patients were ethnically white (61.48%), male (66.72%), living in the counties (86.59%), married (46.84%), and insured (74.73%). The most common TNM stages were T1NOS (74.42%), N1 (73.96%), and M0 (65.95%), and the predominant AJCC stage was IIB (47.46%). For clinical treatments, only a few patients received primary site surgery and radiotherapy, while over half had chemotherapy. Almost the entire cohort (70.72%) had one malignant tumor. The average follow-up time was 15.01 months. Demographic and clinical characteristics are shown in Table 1.

Identifying variables for the nomogram

In the Cox univariate regression analysis, 14 variables were identified that were associated with OS (p < 0.05). In the Cox multivariate analysis, these factors were integrated, and eight of them were identified as independent prognostic factors related to OS (p < 0.05). These factors were insurance, T stage, summary stage, primary site, radiation code, chemotherapy, surgery, and radiation sequence with surgery. The Cox multivariate analysis showed that uninsured status, lower third of the esophagus, regional esophagus, radiation before surgery, no radiation therapy, and chemotherapy were related to the deterioration of OS. For the T1b stage, esophagectomy served as a protective factor for OS. The Cox analyses for screening factors related to OS are listed in Table 2.

Establishment of the nomogram

The eight factors that influenced prognosis of ESCC were identified from Cox multivariate analysis and entered into the present nomogram

J. Yu, W. Hu, N. Yao et al.

Table 1

Demographic and clinical characteristics of T1 ESCC patients with LNM.

25-44 years 13 (2.00) 9 (1.973) 4 (2.083) 55-44 years 237 (55.5013) 249 (54.493) 108 (52.23) 55-44 years 357 (55.013) 249 (54.493) 108 (52.23) 6clian, years, (108) 68 (7.711,12) 67.19,11.44 70.49,10.45 0.20 108/way thirt (month), means 20 15.01-0.65 14.65,6.64 14.472,1.34 0.14 tace, r(1) 20 (51.313) 44 (2.52.31) 15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.15 0.14 0.14 0.15 0.14 0.14 0.15 0.14 0.1	25.44 years 13 (2,000) 9 (1.97%) 4 (2.08%) 65.45 years 233 (55.001%) 249 (54.49%) 108 (56.25%) 65.46 years 237 (55.01%) 249 (54.49%) 108 (56.25%) Median, years, (10R) 68 (7.19%) 31 (7.22%) 13 (6.77%) Median, years, (10R) 68 (7.19%) 22 (6.57.1%) 17 (60.04%) 0.27 Man, Parific Elements, means 20 17 (2.65.01%) 124 (2.65.1%) 14 (56.01%) 17 (60.04%) 0.77 Manerican Indian/Alaska Native 5 (0.77%) 4 (0.68%) 1 (0.52%) 25 (1.80.2%) 0.85 Sen, rifs) - - 0.28 15 (3.3.48%) 1 (0.52%) 0.85 Karal and Urbar, rifs) - - 0.21 0.85	Variable	Whole cohort $[n = 649]$	Training cohort $[n = 457]$	Validation cohort $[n = 192]$	<i>p</i> -valu
15-64 years 233 (35.002) 166 (36.323) 67 (4.4902) 283 years 46 (7.093) 33 (7.223) 13 (6.778) 283 years 46 (7.093) 33 (7.223) 13 (6.778) 283 years 46 (7.093) 33 (7.223) 13 (6.778) 0.49 283 years 46 (7.093) 33 (7.223) 14 (7.43,14) 0.14 283 years 46 (7.093) 123 (7.6343) 40 (3.5783) 14 284 years 17 (7.66403) 123 (7.6343) 13 (7.6373) 10 (5.373) Warcian Indian/Marka Nature 72 (1.243) 13 (6.6523) 129 (67.198) 01 (2.193) Warcian Indian/Marka Nature 73 (1.63.288) 133 (6.6523) 129 (67.198) 021 (0.433) Warcian Indian/Marka Nature 75 (1.15.03) 58 (1.62.93) 17 (8.001,03) 01 (0.193) Umerian Indian/Marka Nature 75 (1.15.03) 58 (8.5.123) 17 (8.001,03) 01 (0.233) Umerian Indian/Marka Nature 75 (1.15.03) 58 (8.5.123) 17 (8.001,03) 01 (0.233) Wareid 121 (8.5.833) 13 (0.7313) 13 (0.73	85 64 gens 233 (55.001) 166 (56.322) 67 (4.4902) 285 years 46 (7.098) 33 (7.228) 13 (6.778) 285 years 46 (7.098) 33 (7.228) 44 (5.5323) 285 years 17 (2.6580) 12 (5.6942) 40 (5.5323) Ware 72 (7.258) 48 (10.508) 1 (5.532) Ware 73 (1.1283) 15 (3.3483) 63 (3.2813) 63 (3.2813) Sian/Pacific Islander 73 (1.1283) 10 (2.198) 12 (1.643) 65 (5.208) 129 (67.198) Gomp riral 12 (1.853) 56 (8.6528) 38 (8.122) 17 (8.001) 65 (1.208) 17 (8.653) 12 (1.643) Gome riral 120 (1.5183) 22 (1.043) 37 (1.527) 10 (2.198) 13 (0.7318) 12 (1.283) 10 (2.198) 11 (2.298) 17 (8.573) 10 (5.298) 10 (7.278) 10 (5.668) 10 (5.678					0.977
55-44 persis 375 (55.01%) 249 (54.49%) 106 (52.28) Median, years, (QR) 68.172+11.25 67.19±11.44 70.49±10.45 0.20 Median, years, (QR) 68.172+11.25 67.19±11.44 70.49±10.45 0.21 Mark 172 (25.50%) 123 (25.91%) 40 (25.57%) 0.37 Mark 172 (25.50%) 123 (25.91%) 40 (25.57%) 0.37 Mark 172 (25.50%) 123 (25.91%) 40 (25.57%) 0.86 Mark 172 (25.50%) 123 (25.91%) 0.3 (22.81%) 0.86 Mark 43 (66.72%) 394 (66.52%) 129 (67.19%) 0.86 Mark 71 (15.28%) 39 (46.51%) 12 (45.37%) 0.3 (22.81%) 0.50 Mark 73 (15.10%) 58 (12.28%) 17 (80.50%) 0.50 <	55.44 years 37 (55.01%) 249 (54.49%) 106 (52.3%) Median years, (108) 68.17=11.25 67.19±11.44 70.49±10.45 0.22 Median years, (108) 68.17=11.25 67.19±11.44 70.49±10.45 0.22 Mare, rt 3)		. ,			
sis years 46 (2008) 33 (2.228) 13 (6.278) vectorial evolution (nonthis), means-50 1501-065 1445e_0.64 1447e_1.34 0.44 white 99 (61.481) 282 (61.713) 117 (60.943) 7 Wate 99 (61.481) 282 (61.713) 117 (60.943) 7 Wate 99 (61.481) 282 (61.713) 10 (2.523) 0 Simplantin Endom (Alaska Native 5 (0.728) 40 (0.5632) 10 (2.193) 0.21 (0.008) 25 (1.3283) 0.86 Simplantin Endom (Alaska Native 5 (0.2683) 129 (67.198) 0.21 (0.008) <t< td=""><td>six yars 46 (2008) 33 (2.228) 13 (6.778) vectorial (volume) 65.1721.123 67.1921.144 70.4921.045 0.22 vibue 97 14665.054 144.72,134 0.14 vibue 99 123 (2.6313) 117 (60.9435) 72 vibue 99 123 (2.6313) 149 (2.522) 0 simplantic indian/Alasia Native 5 (0.773) 4 (0.883) 10.0523) 0 simplantic indian/Alasia Native 5 (0.733) 4 (0.6523) 129 (6.7193) 0.21 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0.21 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0.10 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0 omp rual 95 (6.0530) 389 (85.123) 17 (8.853) 0 omp rual 12 (1.838) 2 (2.0133) 37 (1.927) 0 Natrial Status, r (3) 42 (1.833) 6 (2.01</td><td>15-64 years</td><td>233 (35.90%)</td><td>166 (36.32%)</td><td>67 (34.90%)</td><td></td></t<>	six yars 46 (2008) 33 (2.228) 13 (6.778) vectorial (volume) 65.1721.123 67.1921.144 70.4921.045 0.22 vibue 97 14665.054 144.72,134 0.14 vibue 99 123 (2.6313) 117 (60.9435) 72 vibue 99 123 (2.6313) 149 (2.522) 0 simplantic indian/Alasia Native 5 (0.773) 4 (0.883) 10.0523) 0 simplantic indian/Alasia Native 5 (0.733) 4 (0.6523) 129 (6.7193) 0.21 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0.21 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0.10 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0 omp rual 12 (1.853) 10 (2.195) 2 (1.043) 0 omp rual 95 (6.0530) 389 (85.123) 17 (8.853) 0 omp rual 12 (1.838) 2 (2.0133) 37 (1.927) 0 Natrial Status, r (3) 42 (1.833) 6 (2.01	15-64 years	233 (35.90%)	166 (36.32%)	67 (34.90%)	
hedia, years, (QR) 68, 7; 1; 1, 25 67, 3; 4; 1, 45 70, 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4;	Idealia, years, (UQ) 68, 17, 11, 25 67, 19, 11, 44 70, 49, 10, 45 0.22 iace, n (x) 117 (60, 94) 0.77 0.85 0.77 itace, n (x) 123 (26, 91, 3) 49 (25, 25, 3) 0.77 itack in (anity), itace, n (x) 40 (08, 85) 11, (52, 3) 0.85 itacin, italian/Alaska Native 73 (11, 28, 3) 46 (08, 22, 3) 0.63 (22, 81, 3) 0.63 (22, 81, 3) 0.63 (22, 81, 3) 0.73 (10, 82, 3) 0.73 </td <td>5-84 years</td> <td>357 (55.01%)</td> <td>249 (54.49%)</td> <td>108 (56.25%)</td> <td></td>	5-84 years	357 (55.01%)	249 (54.49%)	108 (56.25%)	
ablew-ip time (months), means_SD 15.01.06.5 1.465e.06.4 1.472, 1.4 0.14 white 399 (61.48%) 282 (61.71%) 1.17 (60.94%) 7 tack 772 (25.50%) 1.23 (26.13%) 49 (25.52%) 0.33 (26.13%) 94 (25.52%) 0.33 (26.13%) 0.33	allow-ip time (months), mean_SD 15.01.06.5 1.465e_06.4 1.4.7e_1.3.4 0.1.4 White 399 (61.483) 282 (61.713) 1.17 (60.943) 7 Mine 399 (61.483) 282 (61.713) 1.17 (60.943) 7 mericin Indian/Alasta Natve 5 (0.773) 4 (0.883) 1 (0.523) 6 ex, n (3) 53 (33.483) 63 (32.813) 0.86 7 0.81 map, rual 121 (23.533) 10 (46.523) 129 (61.193) 0.21 0.21 0.01 0.21 0.01 0.21 0.01	≥85 years	46 (7.09%)	33 (7.22%)	13 (6.77%)	
ace, n (3)	ace, n (3)	/ledian, years, (IQR)	68.17±11.25	67.19±11.44	70.49±10.45	0.201
ace, n (3)	ace, n (3)	ollow-up time (months), mean±SD	15.01±0.65	14.66 ± 0.64	14.47±1.34	0.149
black 172 (26,503) 123 (26,913) 49 (25,523) marican India/Jacks Native 73 (11,253) 48 (10,504) 25 (13,023) sian/Partific Islander 73 (11,253) 48 (10,502) 25 (13,023) emale 216 (33,283) 153 (33,483) 63 (22,813) 03 (66,523) omp runal 12 (1.853) 10 (2.19%) 21 (10,433) ounties 55 (86,593) 389 (85,123) 173 (90,103) otamitad 75 (11,565) 58 (12,693) 17 (8,853) daried 30 (44,63,43) 26 (45,513) 36 (50,001) interse 55 (86,503) 39 (85,123) 37 (11,523) daried 80 (13,108) 65 (14,223) 37 (11,523) interse 39 (60,133) 30 (6,553) 9 (46,853) viewored 92 (14,183) 62 (13,373) 37 (15,273) insarde 39 (60,133) 30 (6,553) 9 (46,853) insarde 92 (14,183) 62 (13,373) 15 (70,313) insarde 92 (14,183) 63 (14,223) 10 (15,23)	lack 172 (26.508) 123 (26.918) 49 (25.528) merican India/Jacka Native 73 (11.25%) 48 (10.50%) 25 (13.02%) sian/Partific Islander 73 (11.25%) 48 (10.50%) 25 (13.02%) emale 216 (33.28%) 135 (33.48%) 63 (23.81%) 03 (25.17%) omp rural 12 (1.85%) 10 (2.19%) 21 (10.45%) 02.1 omp rural 12 (1.85%) 10 (2.19%) 12 (1.85%) 03 (12.69%) 02.1 omp rural 12 (1.85%) 10 (2.19%) 2 (10.42%) 01.0 0.5 daried 304 (46.84%) 206 (45.51%) 30 (10.52%) 01.0 0.5 daried 30 (41.88%) 62 (13.37%) 30 (15.62%) 01.1 0.1 0.24 inscrute 30 (60.13) 30 (6.55%) 9 (45.98%) 0.24 0.33					0.778
lack 172 (26,503) 123 (26,913) 49 (25,523) merican India/Asko Native 73 (11,253) 48 (10,502) 25 (13,023) sian/Partific Islander 73 (11,253) 48 (10,502) 25 (13,023) emale 216 (33,283) 135 (33,483) 63 (22,813) 00 omp rural 12 (1,853) 10 (2,193) 21 (10,433) 00 ounties 55 (86,503) 389 (85,123) 173 (90,103) 00 farital Strus, n (%) 75 (11,568) 56 (2,003) 06 (50,003) 05 farital Strus, n (%) 77 (11,258) 92 (19,188) 92 (0,133) 17 (15,273) 01 (5,273) funderide 39 (6,1513) 05 (6,5513) 94 (6,973) 024 issuration 39 (6,013) 30 (6,553) 13 (7,0313) 01 (5,273) funderidadi 122 (18,080) 80 (17,3113) 04 (21,883) 01 issuration 42 (6,473) 20 (13,373) 15 (7,0313) 03 (6,553) 10 (21,883) 01 issuration 42 (6,474) 20 (13,370) 15 (7,033)	lack 172 (26,503) 123 (26,913) 49 (25,523) merican India/Aska Native 73 (11,253) 48 (10,502) 25 (13,023) sian/Partific Islander 73 (11,253) 48 (10,502) 25 (13,023) emale 216 (33,283) 135 (33,483) 63 (22,813) 05 (65,023) omp rural 12 (1,853) 10 (2,193) 21 (10,433) 02,1000) ounties 56 (86,533) 389 (85,122) 173 (90,103) 05 (73,130) farried 304 (46,843) 206 (45,513) 39 (10,22) 010,422) invarried/Single 129 (11,883) 92 (10,422) 010,422) 010,422) invarried/Single 30 (6,1513) 30 (15,653) 9 (4,693) 02,433 insumatic Recode, n (%) 39 (6,013) 30 (5,653) 135 (70,318) 04 issumatic Recode, n (%) 42 (5,473) 30 (75,593) 15 (70,318) 04 issumatic Recode, n (%) 42 (1,473) 13 (70,373) 13 (70,318) 04 issumatic Recode, n (%) 42 (1,473) 14 (74,473) 16 (4,33,703) 17 (8,85		399 (61.48%)	282 (61.71%)	117 (60.94%)	
merican Indian/Alaska Native 5 (0.77x) 4 (0.88%) 1 (0.52x) 0.86 sin/Partific Standard 12, 25%) 48 (10.50%) 25 (13.02%) 0.86 ex, n (%) 0.86 ernale 210 (13.28%) 153 (33.48%) 63 (23.21%) 0.86 ernale 433 (66.72%) 304 (66.52%) 129 (67.19%) 0.21 and Huhan, n (%) 0.21 omp rural 12 (1.85%) 10 (2.19%) 2 (1.04%) 0.21 outles 552 (86.59%) 398 (85.12%) 173 (90.10%) 0.21 than 75 (11.56%) 58 (12.69%) 173 (90.10%) 0.21 binored 552 (86.59%) 398 (85.12%) 20 (10.42%) 0.21 binored 552 (86.59%) 398 (65.12%) 20 (10.42%) 0.21 binored 552 (86.59%) 398 (65.12%) 20 (10.42%) 0.25 binored 552 (86.59%) 398 (71.57%) 30 (15.52%) 0.21 binored 552 (86.59%) 398 (71.57%) 30 (15.52%) 0.21 binored 552 (86.59%) 350 (76.59%) 135 (70.31%) 0.21 binored 455 (74.73%) 30 (75.59%) 135 (70.31%) 0.21 binored 425 (74.73%) 30 (75.59%) 137 (72.69%) 1.25 binored 425 (74.73%) 30 (75.59%) 137 (72.69%) 1.25 binored 425 (74.73%) 10 (13.75%) 10 (21.83%) 1.25 binored 425 (74.73%) 10 (13.75%) 12 (73.78%) 12 (73.78%) 12 (75	merican Indian/Alaska Native 5 (0.77x) 4 (0.88x) 1 (0.52x) 0.88 sin/Partific Standardr 73 (11.25x) 48 (10.50x) 25 (13.02x) 0.88 ex, n (x) 0.82 ex, n (x) 0.82 frial Status, n (x) 0.82 ex, n (x) 0.85 ex, n (x) 0.95 ex, n (x) 0.95 ex		. ,			
sian/Parfiel fishander 73 (11.25%) 48 (10.50%) 25 (13.02%) 0.86 (55.2%) 153 (33.48%) 63 (23.81%) 0.86 (55.2%) 0.94 (65.5%) 129 (67.1%) 0.87 (55.2%) 0.94 (65.5%) 129 (67.1%) 0.05 (55.7%) 0.94 (65.5%) 129 (67.1%) 0.05 (55.7%) 0.94 (65.5%) 129 (67.1%) 0.05 (55.7%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.95 (55.5%) 0.1	sian/Parfiel islander 73 (11.25%) 48 (10.50%) 25 (13.02%) 0.86 emale 216 (33.28%) 153 (33.48%) 63 (32.81%) 0.86 image and Urban, n (%) 0.21% 0.05%) 349 (65.52%) 129 (67.9%) 0.21% image and Urban, n (%) 0.21%		. ,			
ex, $n(3)$ 216 (3.2.83) 153 (33.483) 63 (32.418) 0.86 Male 433 (66.723) 304 (66.523) 129 (67.193) 0.21 imp rural 12 (1.855) 10 (2.195) 2 (1.043) 0.21 imp rural 12 (1.855) 10 (2.195) 2 (1.043) 0.21 intries 552 (86.593) 389 (85.122) 173 (90.103) 0.53 intried 304 (46.843) 208 (45.513) 96 (50.005) 0.53 ibrocced(5parted 356 (13.103) 63 (14.223) 20 (10.422) 100.005) immarried(5/fingle 129 (14.883) 92 (20.133) 37 (19.273) 10.522) inknown 39 (50.13) 30 (5.563) 9 (4.693) 0.33 inisured 42 (6.473) 30 (17.513) 42 (2.183) 10 inisured 42 (6.473) 30 (17.513) 42 (1.883) 13 is5.4-Midd(14003) 23 (5.033) 17 (8.833) 15 15.4-Midd(14003) 21 (1.983) 15 is5.4-Midd(14003) 22 (1.384) 16 (1.633) 13 (6.783) 16 (1.993) 15 is5.4-Midd(14003) 21 (1.994)<	ex, $n(3)$ 216 (3.2.83) 153 (33.488) 63 (32.413) 63 Ale 433 (66.723) 304 (66.523) 129 (67.193) 0.21 imp rural 12 (1.85%) 10 (2.19%) 2 (1.04%) 0.21 intiges 552 (86.59%) 389 (85.12%) 173 (90.10%) 0.55 intiges 552 (86.59%) 389 (85.12%) 173 (90.10%) 0.56 intiges 552 (86.59%) 389 (85.12%) 20 (10.42%) 0.56 intiges 522 (86.59%) 389 (85.12%) 20 (10.42%) 0.56 intiges 129 (11.88%) 62 (13.57%) 30 (15.62%) 19 (4.69%) 0.52 intiges 22 (14.88%) 62 (13.57%) 31 5 (70.31%) 0.52 0.42 intiges 12 (18.80%) 80 (75.59%) 13 5 (70.31%) 0.42 0.43 0.43 0.53 0.55 0.43 0.55 0.43 0.55 0.42 0.43 0.55 0.42 0.43 0.55 0.43 0.55 0.43 0.55 0.44 0.56 0.42 0.43 0.44 0.56 0.42 0.43 0.56 0.		. ,			
emale (* 216 (33.28%) 153 (33.48%) 63 (32.81%) (* * * * * * * * * * * * * * * * * * *	emale (1) (3) (3) (3) (3) (3) (4) (6) (5) (3) (3) (4) (6) (5) (3) (3) (4) (6) (5) (5) (3) (4) (6) (5) (5) (5) (5) (6) (5) (5) (5) (6) (5) (5) (5) (6) (5) (5) (5) (5) (6) (5) (5) (5) (5) (6) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5	•	,5 (11.25%)	10 (10.50%)	25 (15.62.6)	0.860
Ale 43 (66.72x) 304 (65.52x) 129 (67.19x) 0.21 ionp rual 12 (1.85x) 10 (2.19x) 2 (1.04x) 0.21 ionp rual 562 (66.50x) 389 (85.12x) 179 (00.10x) 0.50 irban 75 (11.56x) 58 (12.60x) 17 (8.55x) 0.50 Arried 304 (46.84x) 208 (45.51x) 96 (50.00x) 0.50 Morried 304 (46.84x) 20 (84.52x) 20 (10.42x) 0.50 Immarried/Single 129 (19.88x) 92 (20.13x) 37 (19.27x) 0.24 Insurance 85 (17.07x) 30 (6.56x) 9 (4.69x) 0.24 nsurance 85 (74.73x) 350 (77.59x) 135 (70.31x) 0.24 nsurance 42 (6.47x) 27 (5.91x) 15 (7.81x) 0.43 15.0-bracic esophagus 41 (12.21x) 58 (12.60x) 37 (19.82x) 13 13.15 15.1-bracic esophagus 41 (12.48x) 58 (12.60x) 37 (19.82x) 13 14.32x) 13 14.32x) 15.1-bracic esophagus 13 (12.48x) 58 (12.60x) 37 (19.82x) 13 15.15 14.20x)	Ale 43 (66.72x) 304 (66.52x) 12 (2 (7.19x) 0.21 ionp rual 12 (1.85%) 10 (2.19x) 2 (1.04%) 0.21 ionp rual 562 (66.50x) 389 (85.12x) 17 (8.010x) 0.50 irban 7 (1.56x) 58 (12.69x) 17 (8.85x) 0.50 irban 7 (1.156x) 58 (12.69x) 20 (10.42x) 0.50 iborced/Sparated 85 (1.310x) 65 (1.42.2x) 30 (10.42x) 0.104.2x) iborced/Sparated 85 (74.73x) 30 (17.51x) 30 (15.62x) 0.24 issurance Recode, n (x) 39 (6.01x) 30 (6.56x) 9 (4.69x) 0.24 issurance Recode, n (x) 30 (6.15x) 21 (15.37x) 42 (12.88x) 0.43 issurance Recode, n (x) 12 (18.00x) 80 (17.51x) 42 (18.33x) 0.43 issurance Recode, n (x) 12 (12.62x) 58 (12.69x) 32 (11.98x) 0.43 issurance Recode, n (x) 12 (12.73x) 15 (17.51x) 15 (1.69x) 23 (11.98x) 0.43 issurance Recode, n (x) 13 (2.62x) 14 (16.92x) 13 (16.23x) 13 (15.23x) 0.13		216 (33 28%)	153 (33 48%)	63 (32 81%)	0.000
			· · ·			
iomp rund 12 (1.85%) 10 (2.19%) 2 (1.04%) ionntes 562 (86.5%) 389 (85.12%) 179 (90.10%) irban 75 (11.56%) 58 (12.69%) 179 (90.10%) Arried 304 (46.84%) 208 (45.51%) 96 (50.00%) 0.50 Married 305 (14.22%) 20 (10.42%) 0.10 (42%) 0.10 (42%) Immarried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) 0.10 (42%) Inknown 39 (6.01%) 30 (6.56%) 9 (4.69%) 0.24 inknown 39 (6.17%) 22 (13.57%) 15 (7.31%) 0.43 inknown 42 (2.47%) 21 (6.35%) 16 (8.33%) 0.175.13% insured 42 (2.47%) 21 (6.35%) 16 (8.33%) 15 (7.51%) 15 (7.51%) 0.43 15.1-Dirocic cosphagus 41 (12.48%) 58 (12.60%) 23 (11.98%) 0.24 isade 1 20 (3.98%) 17 (3.72%) 56 (29.17%) 15 (20.60%) 0.24 isade 1 20 (3.98%) 17 (3.72%) 56 (29.17%) 0.51	iong runi 12 (1.85%) 10 (2.19%) 2 (1.04%) ionntes 562 (86.5%) 389 (85.12%) 17 (8.95%) irkial Status, n (%) 0.52 0.55(1.42.3%) 20 (10.42.3%) Arried 304 (46.84%) 206 (4.5.71%) 96 (50.00%) 0.55 Minari (d)Single 129 (19.88%) 92 (20.13%) 37 (19.27%) 0.104.23%) Innarric(d)Single 29 (14.18%) 62 (13.57%) 30 (15.62%) 96 (50.00%) 0.84 widword 32 (14.18%) 62 (13.57%) 30 (15.62%) 91 (46.99%) 0.24 insured 42 (2.473%) 350 (76.59%) 135 (70.31%) 0.43 insured 42 (2.473%) 21 (5.03%) 17 (8.83%) 0.43 15.0-Corcical esophagus 41 (12.48%) 58 (12.69%) 23 (11.98%) 0.43 15.1-Thoracic esophagus 181 (12.48%) 58 (12.69%) 23 (11.98%) 0.24 icade 1 20 (3.95%) 17 (3.72%) 56 (2.91.73) 15.4 if a.410 24 (3.74.44%) 16 (4.50%) 23 (11.98%) 0.24		455 (00.72%)	504 (00.52%)	129 (07.15%)	0.215
banthes 52 (86.5%) 389 (8.1.2%) 172 (90.10%) bhan 75 (11.56%) 58 (12.69%) 17 (8.5%) baried 37 (14.5%) 75 (11.56%) 96 (50.0%) baried 304 (46.84%) 208 (45.51%) 20 (10.42%) baried 212 (19.88%) 92 (20.13%) 37 (19.2%) binored/Separated 85 (13.10%) 65 (14.22%) 20 (10.42%) binored/Separated 212 (19.88%) 92 (20.13%) 37 (19.2%) binored/separated 92 (14.18%) 62 (13.57%) 90 (15.62%) binored 39 (60.1%) 30 (6.56%) 9 (4.69%) binored 93 (60.1%) 30 (6.56%) 9 (4.69%) binored 45 (74.73%) 350 (76.59%) 12 (21.88%) binored 45 (74.73%) 350 (76.59%) 12 (21.88%) binored 42 (64.7%) 27 (5.91%) 15 (7.81%) binored 42 (64.7%) 27 (5.91%) 15 (7.81%) binored 42 (64.7%) 23 (16.78%) 16 (6.33%) binored 42 (64.7%) 23 (16.78%) 15 (6.33%) binored 42 (64.7%) 23 (16.78%) 15 (6.33%) binored 42 (12.48%) 58 (12.69%) 23 (11.98%) binored 47 (7.24%) 31 (6.78%) 15 (6.33%) binored 57 (13.41%) 64 (14.00%) 23 (11.98%) binored 11 240 (35.98%) 17 (3.22%) 65 (33.85%) binored 11 240 (35.98%) 17 (3.22%) 65 (33.85%) binored 13 (2.00%) 107 (3.22%) 65 (33.85%) binored 13 (2.00%) 13 (16.78%) 9 (4.69%) binored 13 (2.00%) 81 (1.75%) 52 (2.60%) binored 13 (2.00%) 81 (1.75%) 52 (2.60%) binored 13 (2.00%) 81 (6.75%) 9 (4.69%) binored 13 (2.00%) 81 (6.75%) 9 (4.69%) binored 13 (2.00%) 83 (73.96%) 142 (73.96%) binored 57 (10.32%) 45 (1.95%) 22 (11.46%) binored 57 (10.32%) 45 (1.95%) 22 (11.46%) binored 13 (2.00%) 83 (73.96%) 142 (73.96%) binored 57 (10.32%) 45 (1.95%) 22 (11.46%) binored 57 (10.32%) 45 (1.95%) 22 (1.16.8%) binored 57 (10.32%) 45 (1.95%) 22 (1.16.8%) binored 57 (10.32%) 45 (1.95%) 22 (1.16.8%)	banthes 52 (86.5%) 389 (8.1,2%) 173 (90.10%) bhan 75 (11.56%) 58 (12.6%) 17 (8.5%) Arritel Status, n (%) Arritel Status, n (%) Barried 304 (46.84%) 208 (45.51%) 20 (10.42%) Innarried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) Widowed 92 (14.18%) 62 (13.57%) 30 (15.62%) Innarried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) Widowed 92 (14.18%) 62 (13.57%) 30 (15.62%) Innarried/Single 129 (19.88%) 92 (20.13%) 30 (15.62%) Innarried 425 (74.73%) 30 (6.56%) 9 (4.69%) Innarried 425 (74.73%) 350 (76.59%) 13 (70.11%) Innary Site - labeled, n (%) Innary Site - labeled, n (%) Insorted 42 (6.47%) 27 (5.11%) 15 (7.81%) Insorted 42 (6.47%) 27 (5.03%) 15 (7.83%) Insorted 42 (6.47%) 27 (5.03%) 15 (7.83%) Insorted 42 (6.47%) 27 (5.03%) 15 (8.33%) Insorted 42 (6.14%) 23 (11.98%) Insorted 47 (7.24%) 31 (6.78%) 16 (8.33%) Insorted esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) Insorted esophagus 81 (12.48%) 17 (3.72%) 56 (29.17%) Insorted esophagus 81 (12.48%) 17 (3.72%) 56 (2.60%) Insorted esophagus 121 (32.51%) 154 (14.00%) 23 (11.98%) Insorted esophagus 121 (32.51%) 157 (38.29%) 65 (33.85%) Insorted esophagus 121 (32.51%) 17 (3.72%) 56 (2.60%) Insorted esophagus 135 (22.00%) 107 (3.72%) 57 (2.60%) Insorted esophagus 135 (22.00%) 107 (3.72%) 57 (2.60%) Insorted (S.00%) 12 (12.80%) 10 (13.81%) 10 (13.23%) Insorted (S.00%) 12 (13.00%) 81 (14.73%) 91 (4.04%) Insorted (S.00%) 13 (6.78%) 91 (6.13.37%) Insorted (S.00%) 13 (6.78%) 91 (6.13.38%) Insorted (S.00%) 13 (6.78%) 91 (6.13.38%) Insorted (S.00%) 13 (6.78%) 91 (6.13.48%) Insorted (S.00%) 13 (6.78%) 91 (6.13.54%) Insorted (S.00%) 13 (6.7		12 (1 95%)	10 (2 10%)	2(104%)	0.21.
bhan 75 58 (12.68x) 77 (8.85x) Arried 304 (46.84%) 206 (45.51x) 96 (50.00%) 0.50 Married 85 (13.10%) 65 (1.42.2%) 20 (10.42%) 0.50 Inmarried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) 0.56 Inknown 29 (16.13%) 62 (13.57%) 30 (15.62%) 0.469%) Insurace 485 (74.73%) 350 (76.59%) 135 (70.31%) 0.24 insurace 485 (74.73%) 350 (76.59%) 135 (70.31%) 0.469%) inmsured 42 (64.7%) 27 (51.1%) 15 (70.31%) 0.42 ininsured 42 (64.7%) 27 (51.2%) 15 (70.31%) 0.42 ininsured 42 (64.7%) 27 (51.2%) 16 (8.33%) 15 (15.60%) 17 (8.85%) 23 (11.98%) 15 (15.60%) 17 (8.85%) 23 (11.98%) 15 (15.60%) 15 (15.60%) 17 (37.2%) 5 (2.60%) 15 (3.50%) 16 (4.20%) 23 (11.98%) 16 (3.38%) 16 (3.38%) 16 (3.38%) 16 (3.38%) 16 (3.38%) 1	bhan 75 58 (12.69%) 77 (8.85%) Arried 304 (46.84%) 208 (45.51%) 96 (50.00%) 0.50 Morried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) 01 Innarried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) 01 Insurance Recorde, n (%) 30 (6.56%) 9 (4.69%) 0.24 insurance 485 (74.73%) 350 (76.59%) 135 (70.31%) 42 (21.88%) insurance Recorde, n (%) 23 (5.03%) 17 (8.85%) 0.43 infisoarde 42 (64.77) 27 (5.91%) 15 (70.31%) 04 infisoarde 42 (64.77) 27 (5.91%) 15 (8.33%) 15 (15.60%) 0.31 infisoarde 42 (64.73) 31 (6.78%) 16 (8.33%) 15 (15.60%) 15 (15.60%) 13 (16.78%) 16 (8.33%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 16 (8.33%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 15 (15.60%) 15 (15.60%)					
			. ,			
			75 (11.56%)	58 (12.69%)	17 (8.85%)	
biocced/Separated 85 (13.0%) 65 (14.22%) 20 (10.4%) Inhanoried/Single 129 (19.88%) 92 (20.13) 37 (19.27%) Vidowed 92 (14.18%) 62 (13.57%) 30 (15.62%) Inknown 39 (6.01%) 30 (6.56%) 135 (70.31%) Insured 485 (74.73%) 350 (76.59%) 135 (70.31%) Insured 42 (6.47%) 27 (5.91%) 15 (7.81%) Ininsured 42 (6.47%) 27 (5.91%) 15 (8.33%) T5.0-Cervical esophagus 40 (6.16%) 23 (5.03%) 17 (8.85%) T5.3-Upper third esophagus 81 (12.48%) 58 (12.60%) 23 (11.88%) T5.4-Modie third esophagus 183 (28.20%) 127 (27.79%) 55 (29.07%) T5.4-Modie third esophagus 183 (28.20%) 127 (27.79%) 55 (29.07%) T3.4-Modie third esophagus 183 (28.20%) 127 (27.79%) 55 (29.07%) Tade I 240 (36.98%) 17 (37.2%) 5 (2.60%) Tade II 240 (36.98%) 17 (47.48%) 9 (4.20%) Tade II 240 (36.98%) 17 (47.48%) <t< td=""><td>hivorced/Separated 85 (13.10%) 65 (14.22%) 20 (10.42%) hinamaried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) 19.27%) 19.07%)</td><td></td><td></td><td></td><td></td><td>0.505</td></t<>	hivorced/Separated 85 (13.10%) 65 (14.22%) 20 (10.42%) hinamaried/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) 19.27%) 19.07%)					0.505
inmarical/single 129 (19.88%) 92 (20.13%) 37 (19.27%) widword 92 (6.1188) 62 (13.57%) 30 (15.62%) inknown 39 (6.01%) 30 (6.56%) 9 (4.69%) 0.24 insured 485 (74.73%) 350 (76.59%) 135 (70.31%) 0.24 insured 42 (6.47%) 27 (5.91%) 15 (70.31%) 0.34 innaved 42 (6.47%) 27 (5.91%) 15 (75.81%) 0.43 15.0-Cervical esophagus 40 (6.16%) 23 (5.03%) 17 (8.85%) 0.31 15.1-Intoracic esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 15 (3.30%) 15.4-Wort third esophagus 113 (3.200%) 127 (27.79%) 56 (2.91.7%) 15.8/9 15.4-Wort third esophagus 113 (3.200%) 17 (3.72%) 56 (2.91.7%) 15.3/9 15.4-Wort third esophagus 113 (3.200%) 17 (3.72%) 56 (2.91.7%) 15.3/9 15.4-Wort third esophagus 113 (3.200%) 17 (3.72%) 53 (3.35.8%) 15.46 15.4-Wort (sophagus 13 (3.005%) 17 (3.72%) 53 (3.35.8%	Inmarical/Single 129 (19.88%) 92 (20.13%) 37 (19.27%) Vidword 92 (14.18%) 62 (13.57%) 30 (15.62%) Inknown 39 (6.01%) 30 (6.56%) 9 (4.69%) 0.24 nsurde 485 (74.73%) 350 (76.59%) 135 (70.31%) 0.24 nmsured 42 (6.47%) 27 (551%) 15 (7.81%) 0.24 ininsured 42 (6.47%) 27 (551%) 15 (7.81%) 0.33 15.0-Cervical esophagus 40 (6.16%) 23 (5.03%) 17 (8.85%) 0.33 15.1-Dirotric esophagus 81 (12.48%) 58 (12.60%) 23 (11.98%) 0.33 15.4-Dirotric desophagus 211 (32.51%) 154 (33.00%) 23 (11.98%) 0.24 iade 1 22 (3.92%) 17 (3.72%) 5 (2.60%) 0.24 iade 1 24 (35.44%) 160 (35.01%) 84 (34.23%) 0.24 iade 11 24 (37.44%) 160 (35.01%) 83 (18.23%) 0.24 iade 11 24 (36.44%) 10 (0.218.8%) 31 (16.15%) 12 iade 11 24 (37.					
Widowed 92 (14.183) 62 (13.573) 90 (15.628) Inknown 39 (6.013) 30 (6.563) 9 (4.693) nsurace 485 (74.733) 350 (76.593) 135 (70.313) nsuraced 485 (74.733) 27 (5.918) 15 (70.313) minsured 42 (6.473) 27 (5.918) 15 (7.618) minsured 42 (6.473) 23 (5.033) 17 (8.858) 15.0-Forcic cosphagus 40 (6.168) 23 (5.038) 17 (8.858) 15.1-Drotacic cosphagus 81 (12.483) 58 (12.693) 23 (11.983) 15.5-Lower third esophagus 81 (12.483) 16 (1.400) 23 (11.983) 15.5-Lower third esophagus 81 (12.433) 17 (3.723) 5 (2.603) 15.4-Middle third esophagus 81 (2.23.93) 17 (3.723) 5 (2.603) 15.4-General third esophagus 183 (28.203) 17 (3.723) 5 (2.603) 15.4-Middle third esophagus 183 (28.203) 17 (3.82.93) 6 (3.338) 15.4-General third esophagus 183 (28.203) 17 (3.82.93) 6 (3.603) 15.4-General third esophagus 183 (28.	Widowed 92 (14.183) 62 (13.578) 90 (15.28) Inknown 39 (6.013) 30 (6.568) 9 (4.693) nsurate 485 (74.733) 350 (76.593) 135 (70.318) nsurated 42 (6.478) 27 (5.918) 15 (70.318) minsured 42 (6.478) 27 (5.918) 16 (8.338) 115.0-forcic cosphagus 40 (6.168) 23 (5.038) 17 (8.858) 115.0-forcic cosphagus 81 (12.483) 58 (12.698) 23 (1.1981) 115.3-fordic cosphagus 81 (12.483) 58 (12.698) 23 (1.1981) 115.3-fordic cosphagus 81 (12.483) 58 (12.698) 23 (1.1981) 115.3-fordic further cosphagus 81 (22.339) 17 (3.728) 56 (2.608) 115.4-fordic further cosphagus 81 (22.398) 17 (3.728) 56 (2.608) 115.4-fordic further cosphagus 81 (22.398) 17 (3.728) 5 (2.608) 115.4-fordic further cosphagus 83 (42.208) 17 (3.728) 5 (2.608) 115.4-fordic further cosphagus 83 (42.208) 17 (3.728) 5 (2.608) 115.4-fordic further cosphagus					
$\begin{split} \begin{array}{cccc} harrown & 39 (6.013) & 30 (6.563) & 9 (4.693) & 0.24 \\ hsured & 485 (74.733) & 50 (76.593) & 135 (70.313) & 0.24 \\ hsured & 42 (6.474) & 80 (17.513) & 42 (21.883) & 0.17.513) & 15 (7.814) & 0.33 \\ hinsured & 42 (6.474) & 27 (5.514) & 15 (7.814) & 0.33 \\ hinsured & 42 (6.474) & 23 (5.033) & 17 (8.853) & 0.33 \\ hinsured & 42 (6.474) & 31 (6.783) & 16 (8.333) & 0.33 \\ hinsured & 42 (2.483) & 31 (16.783) & 16 (8.333) & 0.33 \\ hinsured & 42 (2.483) & 31 (16.783) & 16 (8.333) & 0.33 \\ hind e sophagus & 81 (12.483) & 58 (12.608) & 23 (11.988) & 0.24 \\ hind e sophagus & 11 (3.2.513) & 154 (33.708) & 57 (26.698) & 0.24 \\ hind e sophagus & 11 (3.2.513) & 154 (33.708) & 57 (26.698) & 0.24 \\ hind e sophagus & 11 (3.2.513) & 154 (33.708) & 57 (26.698) & 0.24 \\ hind e hind e sophagus & 121 (3.2.513) & 154 (33.708) & 57 (26.698) & 0.24 \\ hind e hind e sophagus & 133 (28.028) & 17 (3.723) & 5 (2.608) & 0.24 \\ hind e hind & 240 (36.983) & 175 (38.298) & 65 (33.858) & 0.24 \\ hind & 243 (37.448) & 160 (35.018) & 83 (43.238) & 0.24 \\ hind & 243 (37.448) & 160 (35.018) & 83 (43.238) & 0.24 \\ hind & 243 (37.448) & 100 (21.888) & 35 (18.238) & 0.24 \\ hind & 9 (1.303) & 5 (1.0031) & 83 (43.238) & 0.24 \\ hind & 13 (20.08) & 12 (7.47.483) & 9 (147.408) & 0.24 \\ hind & 40 (6.163) & 31 (6.758) & 5 (2.608) & 0.24 \\ hind & 40 (6.163) & 31 (6.758) & 5 (2.608) & 0.24 \\ hind & 40 (6.163) & 31 (6.758) & 2 (10.948) & 0.24 \\ hind & 40 (5.163) & 31 (6.153) & 0.24 \\ hind & 43 (74.243) & 45 (5.33.923) & 66 (34.383) & 0.24 \\ hind & 9 (9 (15.232) & 45 (33.923) & 61 (3.348) & 0.24 \\ hind & 9 (71.92.23) & 38 (73.968) & 142 (73.968) & 0.24 \\ hind & 9 (73.963) & 338 (73.968) & 142 (73.968) & 0.24 \\ hind & 428 (65.953) & 302 (66.083) & 122 (65.574) & 0.24 \\ hind & 53 (74.242) & 190 (41.583) & 17 (3.658) & 0.24 \\ hind & 53 (74.242) & 190 (41.583) & 17 (3.658) & 0.24 \\ hind & 53 (74.242) & 190 (41.583) & 12 (7.36.83) & 0.25 \\ hind & 11 (20.4963) & 12 (7.36.83) & 0.25 \\ hind & 11 (20.4963) & 12 (10.9428) & 0.24 \\ hind & 12 (10.9428) & 10 (2.188) &$	$\begin{split} \begin{array}{cccc} hardson method met$	Inmarried/Single	129 (19.88%)	92 (20.13%)	37 (19.27%)	
		Vidowed	92 (14.18%)	62 (13.57%)	30 (15.62%)	
		Jnknown	39 (6.01%)	30 (6.56%)	9 (4.69%)	
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		· ·			0.24
			485 (74.73%)	350 (76.59%)	135 (70.31%)	
Ininsured 42 (6.47%) 27 (5.91%) 15 (7.81%) ''imary Site - labeled, n (%) 23 (5.03%) 17 (8.85%) 0.43 '15.0-Cervical esophagus 40 (6.16%) 23 (5.03%) 17 (8.85%) 0.43 '15.0-Uper third esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 15 (3.70%) 57 (29.07%) '15.5-Uwer third esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 56 (29.17%) '15.5-Uwer third esophagus 87 (13.41%) 64 (14.00%) 23 (11.98%) 51 (2.60%) '15.6-Wer third esophagus 87 (13.41%) 64 (14.00%) 23 (3.83%) 51 (3.64%) 'irade I 22 (3.39%) 17 (3.72%) 5 (2.60%) 0.24 'irade II 240 (36.98%) 175 (38.29%) 63 (3.38%) 51 (3.64%) 'irade II 243 (2.00%) 100 (21.88%) 33 (18.27%) 51 (2.60%) /VCC Stage, n (%) 100 (21.88%) 31 (6.78%) 9 (4.69%) 0.81 ////////////////////////////////////	Ininsured 42 (6.47%) 27 (5.91%) 15 (7.81%) ''imary Site - labeled, n (%) 23 (5.03%) 17 (8.85%) 0.43 '15.0-Cervical esophagus 40 (6.16%) 23 (5.03%) 17 (8.85%) 0.43 '15.1-Diroatic esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 55 15.4-Middle third esophagus 211 (32.51%) 15.4 (33.70%) 57 (29.69%) 15 55-lower third esophagus 87 (13.41%) 64 (14.00%) 23 (11.98%) 15 55-lower third esophagus 87 (13.41%) 64 (14.00%) 23 (11.98%) 15 35.40per third esophagus 87 (13.41%) 64 (14.00%) 23 (11.98%) 15 36.432.33 15 36.432.33 15 36.432.33 15 36.432.33 15 36.432.33 15 36.432.33 15 15.432.33 15 15.432.33 15 15.432.33 16 16.75% 15.432.33 16 16.75% 16.633.35% 16.75% 16.633.35% 16.75% 16.633.35% 16.75% 16.633.35% 16.75% 16.46.963 16.67% 10.403% 16.75% 16.63			, <i>,</i>	· · ·	
Trimary Site - labeled. n (%) 0.43 115.0-Cervical esophagus 40 (6.16%) 23 (5.03%) 17 (8.85%) 115.1-Thoracic esophagus 47 (7.24%) 31 (6.78%) 16 (8.33%) 115.3-Upper third esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 115.3-Upper third esophagus 81 (12.51%) 154 (33.70%) 57 (29.69%) 115.4-Middle third esophagus 81 (12.51%) 154 (33.70%) 57 (29.69%) 115.8/9-Overlapping lesion/NOS 87 (13.41%) 64 (14.00%) 23 (11.98%) Grade I 22 (3.39%) 17 (3.72%) 5 (2.60%) 57 (34.23%) Grade I 240 (36.98%) 107 (3.82.0%) 66 (33.85%) 57 (34.23%) Grade II 240 (36.98%) 100 (21.88%) 35 (18.23%) 56 (18.23%) Jnknown 135 (20.80%) 100 (21.88%) 35 (18.23%) 58 (4.64%) JNkown 135 (20.80%) 100 (21.88%) 31 (16.15%) 58 (4.64%) Jnkown 135 (20.80%) 100 (21.88%) 31 (16.15%) 58 (4.64%) JNKo 308 (47.46%) 217 (47.48%)	Trimary Site - labeled. n (x) 0.43 115.0-Cervical esophagus 40 (6.16%) 23 (5.03%) 17 (8.85%) 115.0-Cervical esophagus 47 (7.24%) 31 (6.78%) 16 (8.33%) 115.3-Upper third esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 115.3-Upper third esophagus 81 (12.51%) 154 (33.70%) 57 (29.69%) 115.4-Middle third esophagus 83 (28.20%) 127 (27.79%) 56 (29.17%) 115.8/9-Overlapping lesion/NOS 87 (13.41%) 64 (14.00%) 23 (11.98%) Grade 1 22 (3.39%) 17 (3.72%) 5 (2.60%) 57 (24.69%) Grade 1 240 (36.98%) 107 (3.72%) 56 (2.60%) 57 (34.23%) Grade 1 240 (35.98%) 100 (21.88%) 35 (18.23%) 51 (3.62%) Jacke 11 243 (37.44%) 160 (35.01%) 83 (43.23%) 51 (4.69%) Jacke 11 243 (37.44%) 160 (25.01%) 83 (18.23%) 51 (18.69%) Jacke 11 240 (36.98%) 127 (47.48%) 91 (47.40%) 68 (4.69%) Jacke 11 240 (36.16%) 31 (6.15%)	-				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$.2 (0.17/0)	-, (3.31/0)		0 / 3 -
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		40 (6 16%)	22(E02%)	17 (0.05%)	0.45
1:15.2-looper third esophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 1:15.4-Middle third esophagus 183 (28.20%) 127 (27.79%) 56 (29.17%) 1:15.9-lower third esophagus 183 (28.20%) 127 (27.79%) 56 (29.17%) 1:15.9-lower third esophagus 183 (28.20%) 127 (27.79%) 56 (29.17%) 1:15.9-lower third esophagus 183 (28.20%) 17 (3.72%) 56 (29.17%) 1:15.9-lower third esophagus 183 (28.20%) 17 (3.72%) 56 (29.17%) 1:16.40 240 (36.98%) 17 (3.72%) 56 (33.85%) 127 1:rade II 243 (37.44%) 160 (35.01%) 83 (43.23%) 127 1:rade II 243 (37.44%) 160 (21.88%) 35 (18.23%) 0 1:rade II 243 (37.44%) 100 (21.88%) 35 (18.23%) 0 VC Stage, n (%) 13 (20.00%) 8 (1.75%) 9 (4.69%) 0 V 221 (34.05%) 15 (53.39.2%) 66 (34.38%) 0 0 V 211 (34.05%) 15 (53.92%) 22 (11.46%) 0 0 V 221 (34.05%) 38 (73.96%) 12 (10.94%) 0	1:15.2-Uoper third isophagus 81 (12.48%) 58 (12.69%) 23 (11.98%) 1:15.4-Middle third esophagus 183 (28.20%) 127 (27.79%) 56 (29.17%) 1:15.9-Lower third esophagus 183 (28.20%) 127 (27.79%) 56 (29.17%) 1:15.9-lower third esophagus 183 (28.20%) 17 (3.72%) 56 (29.17%) 1:15.9-lower third esophagus 183 (28.20%) 17 (3.72%) 56 (29.17%) 1:16.41 240 (36.98%) 17 (3.72%) 56 (29.17%) 1:16.41 240 (36.98%) 17 (3.72%) 56 (33.85%) 1:16.41 240 (36.98%) 100 (21.88%) 35 (18.23%) 1:16.11 243 (37.44%) 160 (035.01%) 83 (43.23%) 1:16.11 243 (37.44%) 160 (21.88%) 35 (18.23%) 1:16.11 243 (20.80%) 100 (21.88%) 35 (18.23%) 1:16.11 20.08 (47.46%) 21 (40.63%) 16 (53.39.2%) 66 (34.38%) 1:16 30 (47.46%) 21 (33.92%) 66 (34.38%) 10 (10.7%) 1:16 31 (20.00%) 81 (15.35%) 22 (11.46%) 10 (21.90%) 1:16 67 (10.32%) 45 (9.85%) 22 (14.65%)	1 0				
1:5.4-middle third esophagus 211 (22.51k) 15.4 (33.70k) 57 (29.69k) 1:5.5-lower third esophagus 183 (28.20k) 127 (27.79k) 56 (29.17k) 1:5.6) -Overlapping lesion/NOS 87 (13.41k) 64 (14.00k) 23 (11.98k) i:rade, n (%) 0.24 i:rade II 240 (36.98k) 175 (38.29k) 65 (33.85k) i:rade III 243 (37.44k) 160 (53.01k) 83 (43.23k) i:rade III 243 (37.44k) 160 (53.01k) 83 (42.32k) i:rade III 243 (37.44k) 160 (53.01k) 83 (42.08k) i:rade III 243 (20.8k) 5 (1.09k) 4 (20.8k) i:rade III 243 (20.0k) 217 (47.48k) 91 (47.40k) VCC Stage, n (%) 13 (5.07k) 5 (2.60k) 04.69k) V 21 (124.05k) 15 (33.92k) 66 (43.88k) i:Rikown 67 (10.32k) 45 (9.85k) 21 (10.49k) :NoS 483 (74.42k) 344 (75.27k) 19 (97.20k) :NoS 483 (74.42k) 344 (75.27k) 19 (97.40k) :NoS 487 (13.41k) 61 (13.35k) 26 (13.54k) :NoS<	1:5.4-middle third esophagus 211 (22.51k) 154 (33.70k) 57 (29.69k) 1:5.5-lower third esophagus 183 (28.20k) 127 (27.79k) 56 (29.17k) 1:5.6) -Overlapping lesion/NOS 87 (13.41k) 64 (14.00k) 23 (11.98k) i:rade, n (%) 0.24 (3.69k) 175 (38.29k) 65 (3.85k) i:rade II 240 (36.98k) 175 (38.29k) 65 (3.85k) 0.24 i:rade II 243 (37.44k) 160 (53.01k) 83 (43.23k) 0.37 i:rade II 243 (37.44k) 160 (53.01k) 83 (42.08k) 0.81 i:rade III 243 (20.4k) 5 (1.09k) 4 (2.08k) 0.81 i:rade III 243 (20.0k) 10 (21.88k) 9 (147.00k) 0.81 i:rade III 308 (47.46k) 217 (47.48k) 9 (4.69k) 0.81 i:Rade III 308 (47.46k) 217 (47.48k) 9 (4.95k) 0.81 i:Rade III 30 (20.0k) 8 (1.75k) 5 (2.60k) 0.81 i:Rade III 30 (20.0k) 8 (1.75k) 21 (10.94k) 0.72 i:Rade III 99 (15.25k) 68 (14.88k) 31 (16.15k) 0.72		. ,			
115.5-Lower third esophagus 183 (28.20%) 127 (27.79%) 56 (29.17%) 125.8/9-Overlapping lesion/NOS 87 (13.41%) 64 (14.00%) 23 (11.96%) 15.8/9-Overlapping lesion/NOS 87 (13.41%) 64 (14.00%) 23 (11.96%) 17 ade I 22 (3.39%) 17 (3.72%) 5 (2.60%) 0.24 17 ade II 240 (36.98%) 175 (38.29%) 65 (33.85%) 0.35 (34.23%) 17 add III 243 (37.44%) 160 (35.01%) 83 (43.23%) 0.35 (34.23%) 17 add III 243 (37.44%) 160 (35.01%) 83 (43.23%) 0.81 (34.23%) 17 add III 243 (37.44%) 100 (21.88%) 35 (118.23%) 0.81 (34.23%) 18 308 (47.46%) 217 (47.48%) 91 (47.40%) 0.81 (34.82%) IAN 40 (6.16%) 31 (6.78%) 9 (4.69%) 0.72 (10.94%) V 221 (34.05%) 15 (33.92%) 66 (34.36%) 0.72 (10.94%) IAN 99 (15.25%) 68 (14.88%) 31 (16.15%) 0.72 (10.94%) Tha 99 (15.25%) 68 (14.88%) 31 (16.15%) 0.72 (10.94%) Stage, n (%) (7 (10.32%) 46 (10.07%)	115.5-Lower third esophagus 183 (28.20x) 127 (27.79x) 56 (29.17x) 125.8/9-Overlapping lesion/NOS 87 (13.41x) 64 (14.00x) 23 (11.98x) 125.8/9-Overlapping lesion/NOS 87 (13.41x) 64 (14.00x) 23 (11.98x) 13rade I 22 (3.39x) 17 (3.72x) 5 (2.60x) 0.24 13rade II 240 (35.98x) 175 (38.29x) 65 (33.85x) 0.24 13rade II 244 (37.44x) 160 (35.01x) 83 (43.23x) 0.38 13rade IV 9 (1.39x) 5 (1.09x) 4 (2.08x) 0.81 Nknown 135 (20.80x) 100 (21.88x) 35 (18.23x) 0.81 VCS Stage, n (%) 11 (6.78x) 9 (4.69x) 0.81 IIA 40 (6.16x) 31 (6.78x) 9 (4.69x) IIA 40 (6.15x) 31 (10.07x) 21 (10.94x) V 221 (34.05x) 155 (33.92x) 66 (34.38x) 0.72 IIA 99 (15.25x) 68 (14.88x) 31 (16.15x) 0.72 T1A 99 (15.25x) 68 (14.88x) 31 (16.15x) 0.72 Stage, n (%) 12 (10.94x) 12 (10.94x) 0.7240		. ,			
115.8/9-0verlapping lesion/NOS 87 (13.41%) 64 (14.00%) 23 (11.98%) irade, n (%)	115.8/9-0verlapping lesion/NOS 87 (13.41%) 64 (14.00%) 23 (11.98%) irade, n (%)			, <i>,</i>		
Frade, $n (3)$ 121713.72%50.24irade I2223.39%1717.372%50.260%irade I24036.98%175138.29%6505033.85%irade II24337.44%160(35.01%)83(43.23%)05irade IV99(1.39%)5(1.09%)4(2.08%)inknown135(20.80%)100(21.88%)35(11.82%)VCC Stage, $n (%)$ 0217(47.48%)91(47.40%)IIA40(6.16%)31(6.78%)9(4.69%)IIC13(20.00%)8(1.75%)5(2.60%)V221(34.05%)155(3.92%)66(34.38%)Jinknown67(10.32%)46(10.07%)21(10.94%)	Frade, $n (X)$ 1217170.24irade I22 (3.39%)17 (3.72%)5 (2.60%)irade II240 (36.98%)175 (38.29%)65 (33.85%)irade III243 (37.44%)160 (35.01%)83 (43.23%)irade III243 (37.44%)160 (35.01%)83 (43.23%)irade IV9 (1.39%)5 (1.09%)4 (2.08%)inknown135 (20.80%)100 (21.88%)33 (18.23%)VCC Stage, $n (%)$ 00 (21.88%)91 (47.40%)IIA40 (6.16%)31 (6.78%)9 (4.69%)IIC13 (2.00%)8 (1.75%)5 (2.60%)V221 (34.05%)155 (33.92%)66 (34.38%)Jinknown67 (10.32%)46 (10.07%)21 (10.94%)<		183 (28.20%)	127 (27.79%)	56 (29.17%)	
Grade I22 (3.39%)17 (3.72%)5 (2.60%)Grade II240 (36.98%)175 (38.29%)65 (33.85%)Grade II243 (37.44%)160 (35.01%)83 (43.23%)Grade IV9 (1.39%)5 (1.09%)4 (2.08%)Jaknown135 (20.80%)100 (21.88%)91 (47.40%)Jknown308 (47.46%)217 (47.48%)91 (47.40%)IB308 (47.46%)217 (47.48%)91 (47.40%)IB308 (47.46%)116 (57.87)5 (2.60%)V221 (34.05%)155 (33.92%)66 (34.38%)Jaknown67 (10.32%)46 (10.07%)21 (10.94%)C7 (10.32%)46 (10.07%)21 (10.94%)Jaknown67 (10.32%)45 (9.85%)22 (11.46%)Tha99 (15.25%)68 (14.88%)31 (16.15%)V99 (15.25%)68 (14.85%)21 (11.46%)C107 (10.32%)45 (9.85%)22 (11.46%)V99 (15.25%)68 (14.85%)31 (16.15%)V Stage, n (%) $$	Grade I22 (3.39%)17 (3.72%)5 (2.60%)Grade II240 (36.98%)175 (38.29%)65 (33.85%)Grade II243 (37.44%)160 (35.01%)83 (43.23%)Grade IV9 (13.93%)5 (1.09%)4 (2.08%)Jacknown135 (20.80%)100 (21.88%)91 (47.40%)Jknown135 (20.80%)217 (47.48%)91 (47.40%)JKCStage, n (%)116 (78.3%)9 (4.69%)JIC13 (2.00%)8 (1.75%)5 (2.60%)V221 (34.05%)155 (33.92%)66 (34.38%)Jnknown67 (10.32%)46 (10.07%)21 (10.94%)CTage, n (%)7 (10.32%)45 (9.85%)22 (11.46%)Tha99 (15.25%)68 (14.88%)31 (16.15%)Thb67 (10.32%)45 (9.85%)22 (11.46%)TINOS483 (74.42%)344 (75.27%)139 (72.40%)N Stage, n (%) $-$ 0.66N1480 (73.96%)338 (73.96%)142 (73.96%)V265 (10.02%)48 (10.50%)17 (8.85%)V387 (13.41%)61 (13.35%)26 (13.54%)V421 (34.05%)102 (66.08%)126 (65.62%)V50.021(96.03%)12 (10.94%)21 (10.94%)V332 (149.46%)221 (44.86%)107 (52.88%)V421 (49.46%)221 (44.36%)100 (52.08%)V50.021(96.03%)17 (92.19%)26V0428 (65.95%)398 (87.09%)177 (92.19%)V021 (49.46%)221 (44.36%)10 (0.52.08%)<	C15.8/9-Overlapping lesion/NOS	87 (13.41%)	64 (14.00%)	23 (11.98%)	
Grade II240 (36.98%)175 (38.29%)65 (33.55%)Grade III243 (37.44%)160 (35.01%)83 (43.23%)Grade IIV9 (1.39%)5 (1.09%)4 (2.08%)Jnknown135 (20.80%)100 (21.88%)35 (18.23%)VCC Stage, n (%)	Grade II 240 (36.98%) 175 (38.29%) 65 (33.85%) Grade III 243 (37.44%) 160 (35.01%) 83 (43.23%) Grade IV 91 (139%) 5 (1.09%) 4 (2.08%) Jnknown 135 (20.80%) 100 (21.88%) 35 (18.23%) VCC Stage, n (%) 100 (21.88%) 91 (47.40%) 91 (47.40%) IB 308 (47.46%) 217 (47.48%) 91 (47.40%) 081 IIA 40 (6.16%) 31 (6.78%) 9 (4.69%) 081 IIC 13 (2.00%) 8 (1.75%) 5 (2.60%) 072 Stage, n (%) 211 (10.94%) 072 072 Stage, n (%) 66 (14.38%) 31 (16.15%) 072 TINO 67 (10.32%) 45 (9.85%) 22 (11.46%) 072 V1N 480 (73.96%) 338 (73.96%) 142 (73.96%) 08 V3 Stage, n (%) 17 (2.62%) 10 (2.19%) 7 (8.85%) 074 V4 480 (73.96%) 338 (73.96%) 142 (73.96%) 08 V3 Stage, n (%) 17 (2.62%) 10 (2.19%) 7 (8.65%) 08 V42 65 (10.02%)	Grade, n (%)				0.242
Tarde III243 (37.44%)160 (35.01%)83 (43.23%)Tarde IV9 (1.39%)5 (1.09%)4 (2.08%)Jknown135 (20.80%)100 (21.88%)35 (18.23%)VCC Stage, n (%)217 (47.48%)91 (47.40%)IB308 (47.66%)217 (47.48%)91 (47.40%)IB308 (47.66%)217 (47.48%)91 (46.9%)IIIC13 (2.00%)8 (1.75%)5 (2.60%)V221 (34.05%)155 (33.92%)66 (34.38%)Jhknown67 (10.32%)46 (10.07%)21 (10.94%)Ta99 (15.25%)68 (14.88%)21 (14.65%)Tha99 (15.25%)68 (14.88%)21 (14.65%)Tha99 (15.25%)68 (14.88%)21 (14.65%)ThoS483 (74.42%)344 (75.27%)139 (72.40%)NOS483 (74.42%)344 (75.27%)139 (72.40%)Vi Stage, n (%)(10.23%)48 (10.50%)17 (8.85%)V1480 (73.96%)338 (73.96%)142 (73.96%)V265 (110.02%)48 (10.50%)17 (8.85%)V37 (13.61%)10 (2.19%)7 (3.65%)V421 (34.05%)155 (33.92%)66 (34.38%)V317 (2.62%)100 (2.19%)12 (10.94%)Wo21 (34.05%)155 (33.92%)66 (34.38%)Wo21 (34.05%)155 (33.92%)66 (34.38%)Wo21 (34.05%)155 (33.92%)100 (52.08%)Wo21 (34.05%)155 (33.92%)100 (52.08%)Wo21 (40.42%)21 (48.36%)100 (52.08%)<	Trade III243 (37.44%)160 (35.01%)83 (43.23%)Trade IV9 (1.39%)5 (1.09%)4 (2.08%)Jknown135 (20.80%)100 (21.88%)35 (18.23%)VCC Stage, n (%)217 (47.48%)91 (47.40%)IB308 (47.66%)217 (47.48%)91 (47.40%)IB308 (47.66%)217 (47.48%)91 (46.9%)IIIC13 (2.00%)8 (1.75%)5 (2.60%)V221 (34.05%)155 (33.92%)66 (34.38%)Jnknown67 (10.32%)46 (10.07%)21 (10.94%)° Stage, n (%)7 (10.32%)45 (9.85%)22 (11.46%)° Ib67 (10.32%)45 (9.85%)22 (11.46%)° Ibs67 (10.32%)45 (9.85%)22 (11.46%)° NoS483 (74.42%)344 (75.27%)139 (72.40%)° NoS483 (73.96%)138 (73.96%)142 (73.96%)° NoS483 (73.96%)338 (73.96%)142 (73.96%)° Nage, n (%)(10.21%)7 (3.65%)0.91° No428 (65.95%)302 (66.08%)126 (65.62%)° Nage, n (%)(0.21%)71 (36.98%)0.91° No21 (34.05%)155 (33.92%)66 (34.38%)° Nage, n (%)(21 (40.22%)190 (41.58%)71 (36.98%)° Nage, n (%)(21 (40.22%)190 (41.58%)71 (36.98%)° Nage, n (%)(0.00%)(1.91%)0.92° Nage, n (%)(21 (40.22%)190 (41.58%)71 (36.98%)° Nage, n (%)(21 (40.22%)190 (41.58%)71 (36.98%) </td <td>Grade I</td> <td>22 (3.39%)</td> <td>17 (3.72%)</td> <td>5 (2.60%)</td> <td></td>	Grade I	22 (3.39%)	17 (3.72%)	5 (2.60%)	
Grade IV $9 (1.39\%)$ $5 (1.09\%)$ $4 (2.08\%)$ 30 Jnknown135 (20.80\%)100 (21.88\%)35 (18.23\%)	Grade IV 9 (1.39%) 5 (1.09%) 4 (2.08%) 35 (18.23%)Jnknown135 (20.80%)100 (21.88%)35 (18.23%)0.81JNknown308 (47.46%)217 (47.48%)91 (47.40%)0.81IB308 (47.46%)217 (47.48%)9 (4.69%)0.81IIA40 (6.16%)31 (6.78%)9 (4.69%)0.81IIA40 (6.16%)155 (33.92%)66 (34.38%)0.72V221 (34.05%)155 (33.92%)66 (34.38%)0.72Stage, n (%)70.32%)45 (9.85%)22 (11.46%)TIA99 (15.25%)68 (14.88%)31 (16.15%)0.72TIA99 (15.25%)68 (14.88%)31 (16.15%)0.72TINOS483 (74.42%)344 (75.27%)139 (72.40%)0.72NS tage, n (%) $-$ 0.660.730.65%)V1480 (73.96%)338 (73.96%)142 (73.96%)0.66V387 (13.41%)61 (13.35%)26 (13.54%)0.66V387 (13.41%)61 (13.35%)26 (65.62%)0.91V4221 (34.05%)102 (66.08%)126 (65.62%)0.91V3221 (14.05%)17 (36.98%)0.910.91W0428 (65.95%)302 (66.08%)126 (65.62%)0.91W1221 (34.05%)120 (66.08%)121 (10.94%)0.91Stage, n (%)0.91W1221 (34.05%)121 (10.94%)0.91Stage, n (%)0.91W1221 (40	Grade II	240 (36.98%)	175 (38.29%)	65 (33.85%)	
Grade IV9 (1.39%)5 (1.09%)4 (2.08%)Jnknown135 (20.80%)100 (21.88%)35 (18.23%)JQCC Stage, n (%)	Grade IV $9 (1.39\%)$ $5 (1.09\%)$ $4 (2.08\%)$ $35 (18.23\%)$ Inknown $135 (20.80\%)$ $100 (21.88\%)$ $35 (18.23\%)$ 0.81 JKC Stage, $n (\%)$ $308 (47.46\%)$ $217 (47.48\%)$ $91 (47.40\%)$ 0.81 IB $308 (47.46\%)$ $217 (47.48\%)$ $91 (47.40\%)$ 0.81 IIA $40 (6.16\%)$ $31 (6.78\%)$ $9 (4.69\%)$ 0.81 IIA $40 (6.16\%)$ $31 (6.78\%)$ $9 (4.69\%)$ 0.81 IIA $40 (6.16\%)$ $155 (33.92\%)$ $66 (34.38\%)$ 0.72 Stage, $n (\%)$ $7 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ 0.72 Tha $99 (15.25\%)$ $68 (14.88\%)$ $31 (16.15\%)$ 0.72 Tha $99 (15.25\%)$ $68 (14.88\%)$ $31 (16.15\%)$ 0.72 ThoS $483 (74.42\%)$ $344 (75.27\%)$ $139 (72.40\%)$ 0.72 NS tage, $n (\%)$ $7 (10.32\%)$ $45 (9.85\%)$ $22 (11.46\%)$ 0.66 V1 $480 (73.96\%)$ $338 (73.96\%)$ $142 (73.96\%)$ 0.66 V2 $65 (10.02\%)$ $48 (10.50\%)$ $17 (8.85\%)$ 0.66 V3 $87 (13.41\%)$ $61 (13.35\%)$ $26 (15.54\%)$ 0.91 V4 $221 (34.05\%)$ $102 (66.08\%)$ $126 (65.62\%)$ 0.91 V3 $422 (65.95\%)$ $302 (66.08\%)$ $126 (65.62\%)$ 0.91 M0 $428 (65.95\%)$ $302 (66.08\%)$ $126 (65.62\%)$ 0.91 Stath $321 (49.46\%)$ $221 (48.36\%)$ $100 (52.08\%)$ 0.91 Stath $321 (49.46\%)$ <		. ,			
$\begin{array}{llllllllllllllllllllllllllllllllllll$	$\begin{array}{llllllllllllllllllllllllllllllllllll$. ,			
$\begin{array}{cccccccc} & 0.81 & $	$\begin{array}{ccccccc} & 0.81 \\ \mbox{VCC Stage, n} & 0.81 \\ \mbox{IIA} & 308 (47.4\%) & 217 (47.4\%) & 91 (47.4\%) \\ \mbox{IIB} & 308 (47.4\%) & 217 (47.4\%) & 91 (47.4\%) \\ \mbox{IIA} & 40 (6.16\%) & 31 (6.7\%) & 9 (4.6\%) \\ \mbox{IIC} & 13 (2.0\%) & 8 (1.75\%) & 5 (2.60\%) \\ \mbox{V} & 221 (34.05\%) & 155 (33.92\%) & 66 (34.3\%) \\ \mbox{V} & 221 (34.05\%) & 155 (33.92\%) & 66 (34.3\%) \\ \mbox{IIRC} & 13 (2.0\%) & 8 (1.75\%) & 5 (2.60\%) \\ \mbox{V} & 221 (34.05\%) & 155 (33.92\%) & 66 (34.3\%) \\ \mbox{Stage, n} & (\%) & 0.72 \\ \mbox{Ta} & 99 (15.25\%) & 68 (14.8\%) & 31 (16.15\%) \\ \mbox{Tb} & 67 (10.32\%) & 45 (9.85\%) & 22 (11.46\%) \\ \mbox{Tb} & 67 (10.32\%) & 45 (9.85\%) & 22 (11.46\%) \\ \mbox{Tb} & 67 (10.32\%) & 45 (9.85\%) & 22 (11.46\%) \\ \mbox{Tb} & 65 (10.02\%) & 48 (10.50\%) & 17 (8.5\%) \\ \mbox{Value} & 83 (74.42\%) & 344 (75.27\%) & 139 (72.40\%) \\ \mbox{Value} & 480 (73.96\%) & 338 (73.96\%) & 142 (73.96\%) \\ \mbox{Value} & 65 (10.02\%) & 48 (10.50\%) & 17 (8.5\%) \\ \mbox{Value} & 87 (13.41\%) & 61 (13.35\%) & 26 (13.54\%) \\ \mbox{Value} & 87 (13.41\%) & 61 (13.35\%) & 26 (13.54\%) \\ \mbox{Value} & 10 (2.19\%) & 7 (36.5\%) \\ \mbox{Value} & 458 (65.95\%) & 302 (66.08\%) & 126 (65.62\%) \\ \mbox{Value} & 428 (65.95\%) & 302 (66.08\%) & 126 (65.62\%) \\ \mbox{Value} & 428 (65.95\%) & 302 (66.08\%) & 126 (65.62\%) \\ \mbox{Value} & 428 (65.95\%) & 302 (66.08\%) & 126 (65.62\%) \\ \mbox{Value} & 428 (65.95\%) & 302 (66.08\%) & 126 (65.62\%) \\ \mbox{Value} & 428 (65.95\%) & 302 (66.08\%) & 126 (65.62\%) \\ \mbox{Value} & 428 (65.95\%) & 302 (60.08\%) & 17 (9.21\%) \\ \mbox{Value} & 57 (88.60\%) & 398 (87.09\%) & 17 (9.21\%) \\ \mbox{Value} & 57 (88.60\%) & 398 (87.09\%) & 17 (9.21\%) \\ \mbox{Value} & 596 (91.83\%) & 11 (0.22\%) & 0 (0.00\%) \\ \mbox{Value} & 596 (91.83\%) & 11 (0.22\%) & 0 (0.00\%) \\ \mbox{Value} & 596 (91.83\%) & 417 (91.25\%) & 179 (93.23\%) \\ \mbox{Value} & 596 (91.83\%) & 9 (1.97\%) & 0 (0.00\%) \\ \mbox{Value} & 596 (91.83\%) & 9 (1.97\%) & 0 (0.00\%) \\ \mbox{Value} & 596 (91.83\%) & 9 (1.97\%) & 0 (0.00\%) \\ \mbox{Value} & 596 (91.33\%) & 9 (1.97\%) & 0 (0.00\%) \\ \mbox{Value} & 596 (91.83\%) & 9 $. ,		. ,	
B 308 (47.46%) 217 (47.48%) 91 (47.40%) IIA 40 (6.16%) 31 (6.78%) 9 (4.69%) IIA 40 (6.16%) 31 (6.78%) 9 (4.69%) IIC 13 (2.00%) 8 (1.75%) 5 (2.60%) V 221 (34.05%) 155 (33.92%) 66 (34.38%) Jnknown 67 (10.32%) 46 (10.07%) 21 (10.94%) 'Stage, n (%) (710.32%) 45 (9.85%) 22 (11.46%) 'Thb 67 (10.32%) 45 (9.85%) 22 (11.46%) 'TNOS 483 (74.42%) 344 (75.27%) 139 (72.40%) 'N Stage, n (%) (72 65 (10.02%) 48 (10.50%) 17 (8.85%) V2 65 (10.02%) 48 (10.50%) 17 (8.85%) 0.69 V3 87 (13.41%) 61 (13.35%) 26 (13.54%) 0.91 V4 428 (65.95%) 302 (66.08%) 126 (65.62%) 0.91 V4 221 (34.05%) 155 (33.92%) 66 (34.38%) 0.55 ocalized 67 (10.32%) 46 (10.07%) 21 (10.94%) 0.55 ocalized 67 (10.32%) 10 (41.58%) 71 (36.98%) </td <td>BB 308 (47.46%) 217 (47.48%) 91 (47.40%) IIA 40 (6.16%) 31 (6.78%) 9 (4.69%) IIA 40 (6.16%) 31 (6.78%) 9 (4.69%) IIC 13 (2.00%) 8 (1.75%) 5 (2.60%) V 221 (34.05%) 155 (33.92%) 66 (34.38%) Jnknown 67 (10.32%) 46 (10.07%) 21 (10.94%) 'Stage, n (%) 7 71 71 71 'Ta 99 (15.25%) 68 (14.88%) 31 (16.15%) 'Thb 67 (10.32%) 45 (9.85%) 22 (11.46%) 'Thb 67 (10.32%) 45 (9.85%) 22 (11.46%) 'Stage, n (%) 70 139 (72.40%) 0.65 V1 480 (73.96%) 338 (73.96%) 142 (73.96%) V2 65 (10.02%) 48 (10.50%) 17 (8.85%) V3 87 (13.41%) 61 (13.35%) 26 (13.54%) V4 17 (2.62%) 10 (2.19%) 7 (3.65%) V4 221 (34.05%) 155 (33.92%) 66 (34.38%) Oscalized 67 (10.32%) 46 (10.07%) 21 (10.94%) Vat</td> <td></td> <td>135 (20.00%)</td> <td>100 (21.00%)</td> <td>33 (10.25%)</td> <td>0.815</td>	BB 308 (47.46%) 217 (47.48%) 91 (47.40%) IIA 40 (6.16%) 31 (6.78%) 9 (4.69%) IIA 40 (6.16%) 31 (6.78%) 9 (4.69%) IIC 13 (2.00%) 8 (1.75%) 5 (2.60%) V 221 (34.05%) 155 (33.92%) 66 (34.38%) Jnknown 67 (10.32%) 46 (10.07%) 21 (10.94%) 'Stage, n (%) 7 71 71 71 'Ta 99 (15.25%) 68 (14.88%) 31 (16.15%) 'Thb 67 (10.32%) 45 (9.85%) 22 (11.46%) 'Thb 67 (10.32%) 45 (9.85%) 22 (11.46%) 'Stage, n (%) 70 139 (72.40%) 0.65 V1 480 (73.96%) 338 (73.96%) 142 (73.96%) V2 65 (10.02%) 48 (10.50%) 17 (8.85%) V3 87 (13.41%) 61 (13.35%) 26 (13.54%) V4 17 (2.62%) 10 (2.19%) 7 (3.65%) V4 221 (34.05%) 155 (33.92%) 66 (34.38%) Oscalized 67 (10.32%) 46 (10.07%) 21 (10.94%) Vat		135 (20.00%)	100 (21.00%)	33 (10.25%)	0.815
IIA 40 ($\hat{6}, 16\%$) 31 ($\hat{6}, 78\%$) 9 ($\hat{4}, 69\%$) IIC 13 (2,00%) 8 (1,75%) 5 (2,60%) IIC 13 (2,00%) 8 (1,75%) 5 (2,60%) Inknown 67 (10,32%) 46 (10,07%) 21 (10,94%) I f Stage, n (%)	IIA 40 ($\hat{6}$, $\hat{6}$) 31 ($\hat{6}$, 78) 9 ($\hat{4}$, 69) IIC 13 (2 , 00) 8 (1 , 75) 5 (2 , 60°) IIC 13 (2 , 00°) 8 (1 , 75°) 5 (2 , 60°) IIR 221 (34 , 05°) 155 (33 , 92°) 66 (34 , 38°) Inknown 67 (10.32°) 46 (10.07°) 21 (10.94°) T1a 99 (15.25°) 68 (14.88°) 31 (16.15°) T1b 67 (10.32°) 45 (9.85°) 22 (11.46°) T1bb 67 (10.32°) 45 (9.85°) 22 (11.46°) NSage, n (3°) 42 (73.96°) 38 (73.96°) 12 (7.96°) N Stage, n (3°) 42 (73.96°) 38 (73.96°) 17 (8.85°) N2 65 (10.02°) 48 (10.50°) 17 (8.85°) 05 (10.02°) NX 17 (2.62°) 10 (2.19°) 7 (3.65°) 04 (13.58°) 05 (10.02°) VX 17 (2.62°) 10 (2.19°) 7 (3.65°) 04 (10.32°) 66 (34.38°) 05 (3.02°) 04 (10.32°) 10 (2.19°) 10 (2.65° 05 (3.23°) 05 (3.23°)		308 (47 46%)	217 (17 18%)	91 (47 40%)	0.011
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$				· · ·	
$\begin{array}{cccc} {\rm V} & & & 221 (34.05\%) & 155 (33.92\%) & 66 (34.38\%) \\ {\rm Jnknown} & 67 (10.32\%) & 46 (10.07\%) & 21 (10.94\%) & 0.72 \\ {\rm Tstage, } n (\%) & & & 0.72 \\ {\rm Ta} & & 99 (15.25\%) & 68 (14.88\%) & 31 (16.15\%) & 0.72 \\ {\rm Th} & & 67 (10.32\%) & 45 (9.85\%) & 22 (11.46\%) & 0.72 \\ {\rm Th} & & 67 (10.32\%) & 45 (9.85\%) & 22 (11.46\%) & 0.55 \\ {\rm Th} & & 67 (10.32\%) & 45 (19.85\%) & 22 (11.46\%) & 0.69 \\ {\rm Th} & & 480 (73.96\%) & 338 (73.96\%) & 142 (73.96\%) & 0.69 \\ {\rm V1} & & 480 (73.96\%) & 338 (73.96\%) & 142 (73.96\%) & 0.69 \\ {\rm V1} & & 480 (73.96\%) & 338 (73.96\%) & 142 (73.96\%) & 0.69 \\ {\rm V2} & & 65 (10.02\%) & 48 (10.50\%) & 17 (8.85\%) & 0.69 \\ {\rm V3} & & 7 (13.41\%) & 61 (13.35\%) & 26 (13.54\%) & 0.91 \\ {\rm V4} & & 17 (2.62\%) & 10 (2.19\%) & 7 (3.65\%) & 0.91 \\ {\rm V4} & & 17 (2.62\%) & 10 (2.19\%) & 7 (3.65\%) & 0.91 \\ {\rm V4} & & 17 (2.62\%) & 155 (33.92\%) & 66 (34.38\%) & 0.91 \\ {\rm V4} & & 221 (34.05\%) & 155 (33.92\%) & 66 (34.38\%) & 0.91 \\ {\rm vammary stage, } n (\%) & & & & & & & & & & & & & & & & & & &$	$\begin{array}{cccc} \mathrm{V} & & & 221 (34.05\%) & 155 (33.92\%) & 66 (34.38\%) \\ \mathrm{Jnknown} & & 67 (10.32\%) & 46 (10.07\%) & 21 (10.94\%) & 0.72 \\ ``Stage, $n(\%) & & & & & & & & & & & & & & & & & & &$					
Inknown $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ 0.72 'Stage, $n (\%)$ 99 (15.25\%) $68 (14.88\%)$ $31 (16.15\%)$ 0.72 'Ia99 (15.25\%) $68 (14.88\%)$ $31 (16.15\%)$ 0.72 'Ib $67 (10.32\%)$ $45 (9.85\%)$ $22 (11.46\%)$ 0.72 'INOS $483 (74.42\%)$ $344 (75.27\%)$ $139 (72.40\%)$ 0.69 'I 1 $480 (73.96\%)$ $338 (73.96\%)$ $142 (73.96\%)$ 0.69 V1 $480 (73.96\%)$ $48 (10.50\%)$ $17 (8.85\%)$ 0.69 V1 $480 (73.96\%)$ $48 (10.50\%)$ $17 (8.85\%)$ 0.69 V2 $65 (10.02\%)$ $48 (10.50\%)$ $17 (8.85\%)$ 0.69 V3 $87 (13.41\%)$ $61 (13.35\%)$ $26 (13.54\%)$ 0.91 V4 $17 (2.62\%)$ $10 (2.19\%)$ $7 (3.65\%)$ 0.91 V3 $87 (13.41\%)$ $61 (13.35\%)$ $26 (13.54\%)$ 0.91 V4 $17 (2.62\%)$ $10 (2.19\%)$ $7 (3.65\%)$ 0.91 V4 $221 (34.05\%)$ $302 (66.08\%)$ $126 (65.62\%)$ 0.91 V4 $221 (34.05\%)$ $155 (33.92\%)$ $66 (34.38\%)$ 0.55 ocalized $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ 0.55 ocalized $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ 0.55 ocalized $67 (10.32\%)$ $98 (87.09\%)$ $77 (92.19\%)$ 0.27 ocalized $67 (10.32\%)$ $98 (87.09\%)$ $177 (92.19\%)$ 0.27 obe $575 (88.60\%)$ $398 (87.09\%)$ $177 $	Inknown $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ 0.72 Stage, $n (\%)$ 99 (15.25\%) $68 (14.88\%)$ $31 (16.15\%)$ 0.72 'Ia99 (15.25\%) $68 (14.88\%)$ $31 (16.15\%)$ 0.72 'Ib $67 (10.32\%)$ $45 (9.85\%)$ $22 (11.46\%)$ 0.72 'INOS $483 (74.42\%)$ $344 (75.27\%)$ $139 (72.40\%)$ 0.65 'INOS $483 (74.42\%)$ $344 (75.27\%)$ $139 (72.40\%)$ 0.65 'I $480 (73.96\%)$ $338 (73.96\%)$ $142 (73.96\%)$ 0.65 'I $480 (73.96\%)$ $48 (10.50\%)$ $17 (8.85\%)$ 0.65 'Ia $480 (73.96\%)$ $48 (10.50\%)$ $17 (8.85\%)$ 0.65 'Ia $480 (73.96\%)$ $48 (10.50\%)$ $17 (8.85\%)$ 0.91 'Ia $480 (73.96\%)$ $16 (13.35\%)$ $26 (13.54\%)$ 0.91 'Ia $480 (73.96\%)$ $17 (2.62\%)$ 0.91 0.91 'Ia $420 (50.55\%)$ $302 (66.08\%)$ $126 (65.62\%)$ 0.91 'Ia $221 (34.05\%)$ $155 (33.92\%)$ $66 (34.38\%)$ 0.55 ·ocalized $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ 0.55 ·ocalized $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ 0.55 ·ocalized $67 (10.32\%)$ $190 (41.58\%)$ $71 (36.98\%)$ 0.55 ·ocalized $67 (10.32\%)$ $190 (41.58\%)$ $71 (36.98\%)$ 0.55 ·ocalized $67 (10.32\%)$ $190 (41.58\%)$ $71 (36.98\%)$ $0.57 (86.60\%)$ $98 (87.09\%)$ $177 (92.19\%)$ </td <td></td> <td></td> <td></td> <td>. ,</td> <td></td>				. ,	
0.721 Stage, n (%)0.7211a99 (15.25%)68 (14.88%)31 (16.15%)The0.72The0.72The0.72The0.72The0.72The0.72The0.72The0.72The0.72The0.72The0.72The0.72N Stage, n (%)20.72N The0.69N The0.69N The0.69N The Colspan="2">0.72N The Colspan="2">0.69N The Colspan="2">0.69N The Colspan="2">0.69N The Colspan="2">0.69N The Colspan="2">0.69N The Colspan="2">0.660.610.610.610.720.710.620.620.660.660.620.620.660.710.62 <td>Stage, $n (%)$0.72'1a99 (15.25%)68 (14.88%)31 (16.15%)'1b67 (10.32%)45 (9.85%)22 (11.46%)'1NOS483 (74.42%)344 (75.27%)139 (72.40%)N Stage, $n (%)$</td> <td></td> <td></td> <td></td> <td>· · ·</td> <td></td>	Stage, $n (%)$ 0.72'1a99 (15.25%)68 (14.88%)31 (16.15%)'1b67 (10.32%)45 (9.85%)22 (11.46%)'1NOS483 (74.42%)344 (75.27%)139 (72.40%)N Stage, $n (%)$				· · ·	
Ta 99 (15.25%) 68 (14.88%) 31 (16.15%) Tb 67 (10.32%) 45 (9.85%) 22 (11.46%) TINOS 483 (74.42%) 344 (75.27%) 139 (72.40%) Stage, n (%) 0.69 V1 480 (73.96%) 338 (73.96%) 142 (73.96%) 0.69 V1 480 (73.96%) 338 (73.96%) 142 (73.96%) 0.69 V2 65 (10.02%) 48 (10.50%) 17 (8.85%) 0.69 V3 87 (13.41%) 61 (13.35%) 26 (13.54%) 0.91 V4 17 (2.62%) 10 (2.19%) 7 (3.65%) 0.91 V5 0.428 (65.95%) 302 (66.08%) 126 (65.62%) 0.91 M0 428 (65.95%) 302 (66.08%) 126 (65.62%) 0.91 M1 221 (34.05%) 155 (33.92%) 66 (34.38%) 0.55 Socalized 67 (10.32%) 46 (10.07%) 21 (10.94%) 0.55 Segional 261 (40.22%) 190 (41.58%) 71 (36.98%) 0.27 Sone 575 (88.60%) 398 (87.09%) 177 (92.19%) 66 Sefore surgery <	Ta 99 (15.25%) 68 (14.88%) 31 (16.15%) Tb 67 (10.32%) 45 (9.85%) 22 (11.46%) TINOS 483 (74.42%) 344 (75.27%) 139 (72.40%) Stage, n (%) 0.65 V1 480 (73.96%) 338 (73.96%) 142 (73.96%) 0.65 V2 65 (10.02%) 48 (10.50%) 17 (8.85%) 0.65 V3 87 (13.41%) 61 (13.35%) 26 (63.54%) 0.91 V4 17 (2.62%) 10 (2.19%) 7 (3.65%) 0.91 M4 221 (34.05%) 302 (66.08%) 126 (65.62%) 0.91 M1 221 (34.05%) 150 (40.07%) 21 (10.94%) 0.55 Socalized 67 (10.32%) 46 (10.07%) 21 (10.94%) 0.27 Katiatin with surgery, n (%) <td></td> <td>67 (10.32%)</td> <td>46 (10.07%)</td> <td>21 (10.94%)</td> <td></td>		67 (10.32%)	46 (10.07%)	21 (10.94%)	
The67 (10.32%)45 (9.85%)22 (11.46%)11NOS483 (74.42%)344 (75.27%)139 (72.40%)1NOS483 (74.42%)344 (75.27%)139 (72.40%)N stage, n (%)7(73.96%)338 (73.96%)142 (73.96%)V1480 (73.96%)338 (73.96%)142 (73.96%)0.69V1480 (73.96%)338 (73.96%)17 (8.85%)0.69V265 (10.02%)48 (10.50%)17 (8.85%)0.9V387 (13.41%)61 (13.35%)26 (13.54%)0.9V417 (2.62%)10 (2.19%)7 (3.65%)0.91V548 (65.95%)302 (66.08%)126 (65.62%)0.91V4221 (34.05%)155 (33.92%)66 (34.38%)0.91V0221 (34.05%)155 (33.92%)66 (34.38%)0.91vommary stage, n (%)221 (49.46%)221 (48.36%)100 (52.08%)vommary stage, n (%)261 (40.22%)190 (41.58%)71 (36.98%)vone575 (88.60%)398 (87.09%)177 (92.19%)0.27vone575 (88.60%)398 (87.09%)177 (92.19%)0.27vone575 (88.60%)398 (87.09%)177 (92.19%)0.000%vifter surgery40 (6.16%)31 (6.78%)9 (4.69%)0.000%vifter surgery10 (0.15%)179 (93.23%)0.31ving Prim Site, n (%)0 (0.00%)0 (0.00%)0.31ving Prim Site, n (%)0 (0.00%)0 (0.00%)0 (0.00%)ving Prim Site, n (%)0 (0.00%)0 (0	The67 (10.32%)45 (9.85%)22 (11.46%)11NOS483 (74.42%)344 (75.27%)139 (72.40%)1NOS483 (73.96%)338 (73.96%)142 (73.96%)V1480 (73.96%)338 (73.96%)142 (73.96%)V265 (10.02%)48 (10.50%)17 (8.85%)V387 (13.41%)61 (13.35%)26 (13.54%)V417 (2.62%)10 (2.19%)7 (3.65%)V3428 (65.95%)302 (66.08%)126 (65.62%)A1221 (34.05%)155 (33.92%)66 (34.38%)V4221 (34.05%)155 (33.92%)66 (34.38%)V0221 (49.46%)221 (48.36%)100 (52.08%)Valiation with surgery, n (%)21 (49.46%)221 (48.36%)100 (52.08%)Valiation with surgery, n (%)33 (5.08%)27 (5.91%)6 (3.12%)Value Prim Site, n (%)10 (0.5%)10 (0.00%)0 (0.00%)Value Prim Site, n (%)20 (31%)2 (0.44%)0 (0.00%)Value Prim Site, n (%)96 (91.83%)417 (91.25%)179 (93.23%)Value Sophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Value Sophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Value Sophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)					0.729
TINOS $483 (74.42\%)$ $344 (75.27\%)$ $139 (72.40\%)$ N Stage, $n (\%)$	TINOS $483 (74.42\%)$ $344 (75.27\%)$ $139 (72.40\%)$ N Stage, $n (\%)$	î1a	99 (15.25%)		31 (16.15%)	
N Stage, n (%) 0.69 N1 480 (73.96%) 338 (73.96%) 142 (73.96%) N2 65 (10.02%) 48 (10.50%) 17 (8.85%) N3 87 (13.41%) 61 (13.35%) 26 (13.54%) NX 17 (2.62%) 10 (2.19%) 7 (3.65%) M Stage, n (%)	N Stage, n (%) 0.69 N1 480 (73.96%) 338 (73.96%) 142 (73.96%) N2 65 (10.02%) 48 (10.50%) 17 (8.85%) N3 87 (13.41%) 61 (13.35%) 26 (13.54%) NX 17 (2.62%) 10 (2.19%) 7 (3.65%) M Stage, n (%)	1b	67 (10.32%)	45 (9.85%)	22 (11.46%)	
N Stage, n (%)0.69N1480 (73.96%)338 (73.96%)142 (73.96%)V265 (10.02%)48 (10.50%)17 (8.85%)V387 (13.41%)61 (13.35%)26 (13.54%)V387 (13.41%)61 (13.35%)26 (13.54%)V317 (2.62%)10 (2.19%)7 (3.65%)V417 (2.62%)10 (2.19%)7 (3.65%)V548 (65.95%)302 (66.08%)126 (65.62%)M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)0.21 (10.94%)0.55.ocalized67 (10.32%)46 (10.07%)21 (10.94%)kegional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Adiation with surgery, n (%)0.616%)31 (6.78%)9 (4.69%)None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Surg Prim Site, n (%)0 (0.00%)0 (0.00%)Surg Prim Site, n (%)20 (0.31%)2 (0.44%)0 (0.00%)None596 (91.83%)417 (91.25%)179 (93.23%)Sudoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Stophagectomy, NOS <t< td=""><td>N Stage, n (%)0.69N1480 (73.96%)338 (73.96%)142 (73.96%)V265 (10.02%)48 (10.50%)17 (8.85%)V387 (13.41%)61 (13.35%)26 (13.54%)V387 (13.41%)61 (13.35%)26 (13.54%)V317 (2.62%)10 (2.19%)7 (3.65%)V417 (2.62%)10 (2.19%)7 (3.65%)V548 (65.95%)302 (66.08%)126 (65.62%)M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)0.21 (10.94%)0.55.ocalized67 (10.32%)46 (10.07%)21 (10.94%)kegional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Adiation with surgery, n (%)0.27 (5.91%)6 (3.12%)None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Surg Prim Site, n (%)0 (0.00%)0 (0.00%)Surg Prim Site, n (%)2 (0.31%)2 (0.44%)0 (0.00%)None596 (91.83%)417 (91.25%)179 (93.23%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Vartial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Sindoscopic therapy9 (1.39%)<!--</td--><td>1NOS</td><td>483 (74.42%)</td><td>344 (75.27%)</td><td>139 (72.40%)</td><td></td></td></t<>	N Stage, n (%)0.69N1480 (73.96%)338 (73.96%)142 (73.96%)V265 (10.02%)48 (10.50%)17 (8.85%)V387 (13.41%)61 (13.35%)26 (13.54%)V387 (13.41%)61 (13.35%)26 (13.54%)V317 (2.62%)10 (2.19%)7 (3.65%)V417 (2.62%)10 (2.19%)7 (3.65%)V548 (65.95%)302 (66.08%)126 (65.62%)M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)0.21 (10.94%)0.55.ocalized67 (10.32%)46 (10.07%)21 (10.94%)kegional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Adiation with surgery, n (%)0.27 (5.91%)6 (3.12%)None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Surg Prim Site, n (%)0 (0.00%)0 (0.00%)Surg Prim Site, n (%)2 (0.31%)2 (0.44%)0 (0.00%)None596 (91.83%)417 (91.25%)179 (93.23%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Vartial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Sindoscopic therapy9 (1.39%) </td <td>1NOS</td> <td>483 (74.42%)</td> <td>344 (75.27%)</td> <td>139 (72.40%)</td> <td></td>	1NOS	483 (74.42%)	344 (75.27%)	139 (72.40%)	
M1480 (73.96%)338 (73.96%)142 (73.96%)M265 (10.02%)48 (10.50%)17 (8.85%)M387 (13.41%)61 (13.35%)26 (13.54%)M377 (2.62%)10 (2.19%)7 (3.65%)M Stage, n (%)7 (3.65%)302 (66.08%)126 (65.62%)M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)67 (10.32%)46 (10.07%)21 (10.94%)Socalized67 (10.32%)46 (10.07%)21 (10.94%)Signal261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Adiation with surgery, n (%) 575 (88.60%)398 (87.09%)177 (92.19%)Sefore surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Sefore and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Astial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Statial esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)Stophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	M1480 (73.96%)338 (73.96%)142 (73.96%)M265 (10.02%)48 (10.50%)17 (8.85%)M387 (13.41%)61 (13.35%)26 (13.54%)M377 (2.62%)10 (2.19%)7 (3.65%)M Stage, n (%)7 (3.65%)302 (66.08%)126 (65.62%)M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)67 (10.32%)46 (10.07%)21 (10.94%)Socalized67 (10.32%)46 (10.07%)21 (10.94%)Stath321 (49.46%)221 (48.36%)100 (52.08%)Joistant321 (49.46%)221 (48.36%)100 (52.08%)Solar575 (88.60%)398 (87.09%)177 (92.19%)Sefore surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Sefore and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Sindoscopic therapy9 (1.39%)9 (1.97%)0 (0.00%)Sindoscopic therapy9 (1.39%)9 (1.51%)3 (1.56%)Sisphagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	V Stage, n (%)				0.690
N265 (10.02%)48 (10.50%)17 (8.85%)N387 (13.41%)61 (13.35%)26 (13.54%)NX17 (2.62%)10 (2.19%)7 (3.65%)MS tage, n (%)	N265 (10.02%)48 (10.50%)17 (8.85%)N387 (13.41%)61 (13.35%)26 (13.54%)NX17 (2.62%)10 (2.19%)7 (3.65%)MS tage, n (%)		480 (73.96%)	338 (73.96%)	142 (73.96%)	
N387 (13.41%) 61 (13.35%) 26 (13.54%) NX17 (2.62%) 10 (2.19%) 7 (3.65%) M Stage, $n(\%)$	N387 (13.41%) 61 (13.35%) 26 (13.54%) NX17 (2.62%) 10 (2.19%) 7 (3.65%) M Stage, n (%)0.91M0428 (65.95%) 302 (6.08%) 126 (65.62%) M1221 (34.05%) 155 (33.92%) 66 (34.38%) summary stage, n (%)0.55.ocalized67 (10.32%) 46 (10.07%) 21 (10.94%) Regional261 (40.22%) 190 (41.58%) 71 (36.98%) Distant321 (49.46%) 221 (48.36%) 100 (52.08%) Sefore surgery, n (%)0.27None575 (88.60%) 398 (87.09%) 177 (92.19%) Before surgery40 (6.16%) 31 (6.78%) 9 (4.69%) After surgery33 (5.08%) 27 (5.91%) 6 (3.12%) Before and after surgery1 (0.15%) 1 (0.22%) 0 (0.00%) Surg Prim Site, n (%)0.31None596 (91.83%) 417 (91.25%) 179 (93.23%) Sindoscopic therapy2 (0.31%) 2 (0.44%) 0 (0.00%) Sindoscopic therapy9 (1.39%) 9 (1.97%) 0 (0.00%) Sindoscopic therapy9 (1.39%) 6 (1.31%) 3 (1.56%) Sindagectomy9 (1.39%) 6 (1.31%) 3 (1.55%) Sindagectomy, NOS33 (5.08%) 23 (5.03%) 10 (5.21%)					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	NX17 (2.62%)10 (2.19%)7 (3.65%)M Stage, n (%)		, ,	. ,		
M Stage, n (%)0.91M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)0.55.ocalized67 (10.32%)46 (10.07%)21 (10.94%)kegional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Adiation with surgery, n (%)0.616%)31 (6.78%)9 (4.69%)None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Stug Prim Site, n (%)00.00%)0.31None596 (91.83%)417 (91.25%)179 (93.23%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Yartial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Stophagectomy9 (1.39%)23 (5.03%)10 (5.21%)	M Stage, n (%)0.91M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)0.550.55o.calized67 (10.32%)46 (10.07%)21 (10.94%)kegional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Sadiation with surgery, n (%)0.98 (87.09%)177 (92.19%)None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Surg Prim Site, n (%)0 (0.01%)0 (0.00%)None596 (91.83%)417 (91.25%)179 (93.23%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Yartial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Sicophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)					
M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)0.55.o.calized67 (10.32%)46 (10.07%)21 (10.94%)Regional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Radiation with surgery, n (%)0.27None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Sendoscopic therapy9 (1.39%)9 (1.97%)0 (0.00%)Yartial esophagectomy9 (1.39%)9 (1.31%)3 (1.56%)Stophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	M0428 (65.95%)302 (66.08%)126 (65.62%)M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n (%)0.55.o.calized67 (10.32%)46 (10.07%)21 (10.94%)Regional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Kadiation with surgery, n (%)0.27None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Sindoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Vartial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Cotal esophagectomy9 (1.39%)23 (5.03%)10 (5.21%)		., (2.02/0)		. (3.03%)	0.010
M1221 (34.05%)155 (33.92%)66 (34.38%)Summary stage, n ($\%$)0.55.ocalized67 (10.32%)46 (10.07%)21 (10.94%)Regional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Radiation with surgery, n ($\%$)0.27None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Stone596 (91.83%)417 (91.25%)179 (93.23%)Sendoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Statial esophagectomy9 (1.39%)9 (1.57%)156%)Stophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	M1221 (34.05%) 155 (33.92%) 66 (34.38%) Summary stage, n (%)0.55.ocalized67 (10.32%) 46 (10.07%) 21 (10.94%) Regional261 (40.22%) 190 (41.58%) 71 (36.98%) Distant321 (49.46%) 221 (48.36%) 100 (52.08%) Radiation with surgery, n (%) 00 $(57.5 (88.60\%)$ 398 (87.09%) 177 (92.19%) Sefore surgery40 (6.16%) 31 (6.78%) 9 (4.69%) After surgery33 (5.08%) 27 (5.91%) 6 (3.12%) Sefore and after surgery1 (0.15%) 1 (0.22%) 0 (0.00%) Sing Prim Site, n (%) 00 0100% 000% Sendoscopic therapy2 (0.31%) 2 (0.44%) 0 (0.00%) Artial esophagectomy9 (1.39%) 9 (1.97%) 0 (0.00%) Stophagectomy, NOS33 (5.08%) 23 (5.03%) 10 (5.21%)		128 (65 05%)	202 (66 08%)	126 (65 62%)	0.910
Summary stage, n (%)0.55Localized67 (10.32%)46 (10.07%)21 (10.94%)Regional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Radiation with surgery, n (%) 0.27 0.27None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Surg Prim Site, n (%) 0.31 0.20% None596 (91.83%)417 (91.25%)179 (93.23%)Endoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.31%)3 (1.56%)Esophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	Summary stage, n (%)0.55Localized67 (10.32%)46 (10.07%)21 (10.94%)Regional261 (40.22%)190 (41.58%)71 (36.98%)Distant321 (49.46%)221 (48.36%)100 (52.08%)Radiation with surgery, n (%) 0.27 0.27None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Surg Prim Site, n (%) 0.31 0.31None596 (91.83%)417 (91.25%)179 (93.23%)Endoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Esophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)		· · ·	, <i>,</i>		
Localized $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ Regional $261 (40.22\%)$ $190 (41.58\%)$ $71 (36.98\%)$ Distant $321 (49.46\%)$ $221 (48.36\%)$ $100 (52.08\%)$ Radiation with surgery, $n (\%)$ 0.27 None $575 (88.60\%)$ $398 (87.09\%)$ $177 (92.19\%)$ Before surgery $40 (6.16\%)$ $31 (6.78\%)$ $9 (4.69\%)$ After surgery $33 (5.08\%)$ $27 (5.91\%)$ $6 (3.12\%)$ Before and after surgery $1 (0.15\%)$ $1 (0.22\%)$ $0 (0.00\%)$ Surg Prim Site, $n (\%)$ $596 (91.83\%)$ $417 (91.25\%)$ $179 (93.23\%)$ Sendoscopic therapy $2 (0.31\%)$ $2 (0.44\%)$ $0 (0.00\%)$ Total esophagectomy $9 (1.39\%)$ $9 (1.97\%)$ $0 (0.00\%)$ Esophagectomy, NOS $33 (5.08\%)$ $23 (5.03\%)$ $10 (5.21\%)$	Localized $67 (10.32\%)$ $46 (10.07\%)$ $21 (10.94\%)$ Regional $261 (40.22\%)$ $190 (41.58\%)$ $71 (36.98\%)$ Distant $321 (49.46\%)$ $221 (48.36\%)$ $100 (52.08\%)$ Radiation with surgery, $n (\%)$ 0.27 None $575 (88.60\%)$ $398 (87.09\%)$ $177 (92.19\%)$ Before surgery $40 (6.16\%)$ $31 (6.78\%)$ $9 (4.69\%)$ After surgery $33 (5.08\%)$ $27 (5.91\%)$ $6 (3.12\%)$ Before and after surgery $1 (0.15\%)$ $1 (0.22\%)$ $0 (0.00\%)$ Surg Prim Site, $n (\%)$ $596 (91.83\%)$ $417 (91.25\%)$ $179 (93.23\%)$ Sendoscopic therapy $2 (0.31\%)$ $2 (0.44\%)$ $0 (0.00\%)$ Total esophagectomy $9 (1.39\%)$ $9 (1.97\%)$ $0 (0.00\%)$ Esophagectomy, NOS $33 (5.08\%)$ $23 (5.03\%)$ $10 (5.21\%)$		221 (34.03%)	100 (00.92%)	00 (34.36%)	0.5.5
Regional $261^{\circ}(40.22^{\circ})$ $190^{\circ}(41.58^{\circ})$ $71^{\circ}(36.98^{\circ})$ Distant $321^{\circ}(49.46^{\circ})$ $221^{\circ}(48.36^{\circ})$ $100^{\circ}(52.08^{\circ})$ Radiation with surgery, $n^{\circ}(x)$ $0.27^{\circ}(82.60^{\circ})$ $0.27^{\circ}(92.19^{\circ})$ None $575^{\circ}(88.60^{\circ})$ $398^{\circ}(87.09^{\circ})$ $177^{\circ}(92.19^{\circ})$ Sefore surgery $40^{\circ}(6.16^{\circ})$ $31^{\circ}(6.78^{\circ})$ $9^{\circ}(4.69^{\circ})$ After surgery $33^{\circ}(5.08^{\circ})$ $27^{\circ}(5.91^{\circ})$ $6^{\circ}(3.12^{\circ})$ Before and after surgery $1^{\circ}(0.15^{\circ})$ $1^{\circ}(0.22^{\circ})$ $0^{\circ}(0.00^{\circ})$ Gurg Prim Site, $n^{\circ}(x)$ $596^{\circ}(91.83^{\circ})$ $417^{\circ}(91.25^{\circ})$ $179^{\circ}(93.23^{\circ})$ None $596^{\circ}(91.83^{\circ})$ $417^{\circ}(91.25^{\circ})$ $179^{\circ}(93.23^{\circ})$ Endoscopic therapy $2^{\circ}(0.31^{\circ})$ $2^{\circ}(0.44^{\circ})$ $0^{\circ}(0.00^{\circ})$ Partial esophagectomy $9^{\circ}(1.39^{\circ})$ $9^{\circ}(1.97^{\circ})$ $0^{\circ}(0.00^{\circ})$ Fotal esophagectomy $9^{\circ}(1.39^{\circ})$ $23^{\circ}(5.03^{\circ})$ $10^{\circ}(5.21^{\circ})$	Regional $261^{\circ}(40.22^{\circ})$ $190^{\circ}(41.58^{\circ})$ $71^{\circ}(36.98^{\circ})$ Distant $321^{\circ}(49.46^{\circ})$ $221^{\circ}(48.36^{\circ})$ $100^{\circ}(52.08^{\circ})$ Radiation with surgery, $n^{\circ}(\infty)$ $0.27^{\circ}(88.60^{\circ})$ $398^{\circ}(87.09^{\circ})$ $177^{\circ}(92.19^{\circ})$ None $575^{\circ}(88.60^{\circ})$ $398^{\circ}(87.09^{\circ})$ $177^{\circ}(92.19^{\circ})$ Before surgery $40^{\circ}(6.16^{\circ})$ $31^{\circ}(6.78^{\circ})$ $9^{\circ}(4.69^{\circ})$ After surgery $33^{\circ}(5.08^{\circ})$ $27^{\circ}(5.91^{\circ})$ $6^{\circ}(3.12^{\circ})$ Before and after surgery $1^{\circ}(0.15^{\circ})$ $1^{\circ}(0.22^{\circ})$ $0^{\circ}(0.00^{\circ})$ Gurg Prim Site, $n^{\circ}(\infty)$ $596^{\circ}(91.83^{\circ})$ $417^{\circ}(91.25^{\circ})$ $179^{\circ}(93.23^{\circ})$ None $596^{\circ}(91.83^{\circ})$ $2^{\circ}(0.44^{\circ})$ $0^{\circ}(0.00^{\circ})$ Bendoscopic therapy $2^{\circ}(0.31^{\circ})$ $2^{\circ}(0.44^{\circ})$ $0^{\circ}(0.00^{\circ})$ Partial esophagectomy $9^{\circ}(1.39^{\circ})$ $9^{\circ}(1.97^{\circ})$ $0^{\circ}(0.00^{\circ})$ Bordascophagectomy $9^{\circ}(1.39^{\circ})$ $23^{\circ}(5.03^{\circ})$ $10^{\circ}(5.21^{\circ})$		07 (40 00%)	10 (10 070)	21 (10 0 19/)	0.552
Distant $321 (49.46\%)$ $221 (48.36\%)$ $100 (52.08\%)$ Adiation with surgery, $n (\%)$ 0.27None $575 (88.60\%)$ $398 (87.09\%)$ $177 (92.19\%)$ Before surgery $40 (6.16\%)$ $31 (6.78\%)$ $9 (4.69\%)$ fifter surgery $33 (5.08\%)$ $27 (5.91\%)$ $6 (3.12\%)$ Before and after surgery $1 (0.15\%)$ $1 (0.22\%)$ $0 (0.00\%)$ $596 (91.83\%)$ $417 (91.25\%)$ $79 (93.23\%)$ $6 (3.12\%)$ $6 (1.31\%)$ $2 (0.44\%)$ $0 (0.00\%)$ $2 (0.31\%)$ $9 (1.97\%)$ $0 (0.00\%)$ $6 (1.31\%)$ $3 (1.56\%)$ $6 (50\%)$ $33 (5.08\%)$ $23 (5.03\%)$ $10 (5.21\%)$	Distant $321 (49.46\%)$ $221 (48.36\%)$ $100 (52.08\%)$ Adiation with surgery, $n (\%)$		· · ·	. ,		
Radiation with surgery, n (%)0.27None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)Ifter surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Burg Prim Site, n (%)0 (3.12%)0 (0.00%)None596 (91.83%)417 (91.25%)179 (93.23%)Indoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Varitial esophagectomy9 (1.39%)9 (1.37%)3 (1.56%)Stophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	0.270.27None575 (88.60%)398 (87.09%)177 (92.19%)Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Burg Prim Site, n (%)0.31None596 (91.83%)417 (91.25%)179 (93.23%)Indoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Stophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)					
None $575 (88.60\%)$ $398 (87.09\%)$ $177 (92.19\%)$ Before surgery $40 (6.16\%)$ $31 (6.78\%)$ $9 (4.69\%)$ After surgery $33 (5.08\%)$ $27 (5.91\%)$ $6 (3.12\%)$ Before and after surgery $1 (0.15\%)$ $1 (0.22\%)$ $0 (0.00\%)$ Bone $596 (91.83\%)$ $417 (91.25\%)$ $179 (93.23\%)$ Schoospic therapy $2 (0.31\%)$ $2 (0.44\%)$ $0 (0.00\%)$ Varital esophagectomy $9 (1.39\%)$ $9 (1.97\%)$ $0 (0.00\%)$ Stophagectomy $9 (1.39\%)$ $6 (1.31\%)$ $3 (1.56\%)$ Esophagectomy, NOS $33 (5.08\%)$ $23 (5.03\%)$ $10 (5.21\%)$	None 575 (88.60%) 398 (87.09%) 177 (92.19%) Before surgery 40 (6.16%) 31 (6.78%) 9 (4.69%) After surgery 33 (5.08%) 27 (5.91%) 6 (3.12%) Before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) Before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) Stope 596 (91.83%) 417 (91.25%) 179 (93.23%) Indoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) artial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) Total esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)		321 (49.46%)	221 (48.36%)	100 (52.08%)	
Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Store596 (91.83%)417 (91.25%)179 (93.23%)Schoose (therapy2 (0.31%)2 (0.44%)0 (0.00%)Bartial esophagectomy9 (1.39%)9 (1.37%)0 (0.00%)Storal esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)Scophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	Before surgery40 (6.16%)31 (6.78%)9 (4.69%)After surgery33 (5.08%)27 (5.91%)6 (3.12%)Before and after surgery1 (0.15%)1 (0.22%)0 (0.00%)Stars 0 0 0.31 None596 (91.83%)417 (91.25%)179 (93.23%)Endoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Fotal esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)Esophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)					0.279
After surgery 33 (5.08%) 27 (5.91%) 6 (3.12%) Before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) Sing Prim Site, n (%) 0.31 None 596 (91.83%) 417 (91.25%) 179 (93.23%) Endoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) artial esophagectomy 9 (1.39%) 9 (1.37%) 0 (0.00%) Total esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	After surgery 33 (5.08%) 27 (5.91%) 6 (3.12%) before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) sing Prim Site, n (%) 0.31 None 596 (91.83%) 417 (91.25%) 179 (93.23%) Endoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) artial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) Total esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	None	575 (88.60%)		177 (92.19%)	
After surgery 33 (5.08%) 27 (5.91%) 6 (3.12%) Before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) Sing Prim Site, n (%) 0.31 None 596 (91.83%) 417 (91.25%) 179 (93.23%) Endoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) artial esophagectomy 9 (1.39%) 9 (1.37%) 0 (0.00%) Total esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	After surgery 33 (5.08%) 27 (5.91%) 6 (3.12%) before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) sing Prim Site, n (%) 0.31 None 596 (91.83%) 417 (91.25%) 179 (93.23%) Endoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) artial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) Total esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	Before surgery	40 (6.16%)	31 (6.78%)	9 (4.69%)	
Before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) Surg Prim Site, n (%) 0.31 None 596 (91.83%) 417 (91.25%) 179 (93.23%) Endoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) 'artial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) 'brale sophagectomy 9 (1.39%) 6 (1.31%) 3 (1.56%) Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	Before and after surgery 1 (0.15%) 1 (0.22%) 0 (0.00%) Surg Prim Site, n (%) 0.31 None 596 (91.83%) 417 (91.25%) 179 (93.23%) Endoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) artial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) foral esophagectomy 9 (1.39%) 6 (1.31%) 3 (1.56%) Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	After surgery			6 (3.12%)	
Aurg Prim Site, n (%)0.31None596 (91.83%)417 (91.25%)179 (93.23%)Endoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Potal esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)Scophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	Site, n (%)0.31None596 (91.83%)417 (91.25%)179 (93.23%)Endoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Potal esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)Sophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)		, ,		. ,	
None596 (91.83%)417 (91.25%)179 (93.23%)Endoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Potal esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)Esophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	None596 (91.83%)417 (91.25%)179 (93.23%)andoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)otal esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)sophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)	0.1	·····			0.314
Endoscopic therapy 2 (0.31%) 2 (0.44%) 0 (0.00%) Partial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) Total esophagectomy 9 (1.39%) 6 (1.31%) 3 (1.56%) Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	Endoscopic therapy2 (0.31%)2 (0.44%)0 (0.00%)Partial esophagectomy9 (1.39%)9 (1.97%)0 (0.00%)Total esophagectomy9 (1.39%)6 (1.31%)3 (1.56%)Esophagectomy, NOS33 (5.08%)23 (5.03%)10 (5.21%)		596 (91 83%)	417 (91.25%)	179 (93.23%)	
Partial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) Total esophagectomy 9 (1.39%) 6 (1.31%) 3 (1.56%) Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	Partial esophagectomy 9 (1.39%) 9 (1.97%) 0 (0.00%) Total esophagectomy 9 (1.39%) 6 (1.31%) 3 (1.56%) Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)					
Fotal esophagectomy 9 (1.39%) 6 (1.31%) 3 (1.56%) Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	Fotal esophagectomy 9 (1.39%) 6 (1.31%) 3 (1.56%) Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)					
Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)	Esophagectomy, NOS 33 (5.08%) 23 (5.03%) 10 (5.21%)		. ,			
					. ,	
	Radiation recode, n (%) 0.25		33 (5.08%)	23 (5.03%)	10 (5.21%)	

(continued on next page)

Table 1 (continued)

Variable	Whole cohort $[n = 649]$	Training cohort $[n = 457]$	Validation cohort $[n = 192]$	<i>p</i> -value	
Beam radiation	391 (60.25%)	283 (61.93%)	108 (56.25%)		
Radiation, NOS	6 (0.92%)	3 (0.66%)	3 (1.56%)		
None/Unknown	252 (38.83%)	171 (37.42%)	81 (42.19%)		
Chemotherapy, n (%)				0.927	
Yes	404 (62.25%)	285 (62.36%)	119 (61.98%)		
None/Unknown	245 (37.75%)	172 (37.64%)	73 (38.02%)		
CS extension, n (%)	. ,	. ,	. ,	0.662	
100 mm	74 (11.40%)	51 (11.16%)	23 (11.98%)		
110-170 mm	123 (18.95%)	83 (18.16%)	40 (20.83%)		
210-300 mm	452 (69.65%)	323 (70.68%)	129 (67.19%)		
No. of malignant tumors, n (%)				0.033	
1	459 (70.72%)	337 (73.74%)	122 (63.54%)		
2	151 (23.27%)	95 (20.79%)	56 (29.17%)		
3	39 (6.01%)	25 (5.47%)	14 (7.29%)		
No. of benign tumors, n (%)				0.359	
0	647 (99.69%)	455 (99.56%)	192 (100.00%)		
1	2 (0.31%)	2 (0.44%)	0 (0.00%)		

LNM: lymph node metastases; NOS: Not specific.

SEER data represents a collaboration between the US Centers for Disease Control and Prevention, the National Cancer Institute, and regional and state cancer registries from 18 states of United States.




Fig. 1. Nomogram to predict 1- and 3-year survival probability for T1 lymph node-positive ESCC patients. Medi: Any Medicaid; Surg=surgery status, PE: Partial esophagectomy, TE: Total esophagectomy, EX: Esophagectomy, not specific; Endosco: Endoscopic therapy; RX: Radiation, not specific; Beam: Beam radiation; Before & after S: Radiation before and after surgery, After S: Radiation after surgery, Before S: Radiation before surgery; 15.0: Cervical esophagus, 15.1: Thoracic esophagus, 15.3: Upper third esophagus, 15.4: Middle third esophagus, 15.5: Lower third esophagus, 15.X: Overlapping lesion/not specific.

model. Among these eight factors, radiation sequence with surgery was the most influential for the forecasting of OS, followed by surgery type, chemotherapy status, and T stage. The relative results are shown in Fig. 1.

Nomogram validation

The discrimination ability of the nomogram was evaluated using Cindex and ROC-related AUC. The prediction model's C-index was 0.749 and 0.751 in the training and validation cohort, respectively; both scores were significantly higher than those of the 7th AJCC stage (p < 0.001), which achieved a score of 0.640 and 0.638, respectively (Table 3). Similarly, for the AUCs, the nomogram outperformed the 7th AJCC stage in the training (1-year AUC: 0.799 vs. 0.738; 3-year AUC: 0.810 vs. 0.735, Fig. 2A and 2B) and validation (1-year AUC: 0.817 vs. 0.716; 3-year AUC: 0.756 vs. 0.721, Fig. 2C and 2D) groups. The nomogram had superior discrimination ability compared to that of the 7th AJCC staging system. The calibration curves of the nomogram for 1-year and 3-year OS indicated that the predicted survival probability and the actual observed ones in both training and validation groups matched each other closely (Fig. 3). From the accuracy analysis, the NRI values for the 1-year and 3-year OS probabilities were 0.313 (95% CI: 0.182-0.408) and 0.483 (95% CI: 0.198-0.776) in the training cohort and 0.364 (95% CI: 0.129-0.526) and 0.325 (95% CI: 0.017-0.557) in the validation cohort (Table 3). In addition, the IDI values for the 1-year and 3-year OS probabilities were 0.132 (95% CI: 0.085-0.184) and 0.110 (95% CI: 0.038-0.204) respectively, in the training dataset and 0.171 (95% CI: 0.078-0.257) and 0.161 (95% CI: 0.042-0.275), respectively, in the validation dataset (Table 3). All these results indicated that the present nomogram had improved accuracy compared to the 7th AJCC staging system in predicting OS.

DCA was performed to compare the clinical validity of the nomogram to the 7th AJCC staging system. As shown in Fig. 4A-D, the nomogram achieved greater net clinical benefits across a wide range of threshold probabilities versus the 7th AJCC stage system in both the training cohort and the validation cohort.

Discussion

No comprehensive and personalized prediction model currently exists to evaluate the prognosis for early ESCC patients with lymph nodes

Table 2

Univariate and multivariate Cox analyses for screening factors related to overall survival of T1 ESCC patients with LNM

	Univariate analysis p-		р-	Multiva	р-	
Variable	HR	95%CI	value	HR	95%CI	value
Age						value
25–44 years	1.000			-		
45–64 years	1.110	0.604-2.038	0.737	-	-	-
65–84 years	1.117	0.611-2.039	0.720	-	-	-
≥85years	1.879	0.969-3.646	0.062	-	-	-
Race						
White	1.000			-		
Black	1.160	0.955-1.409	0.136	-	-	-
Ameri Indian/Alaska Native	1.325	0.547-3.208	0.533	-	-	-
Asian/Pacific Islander Sex	1.013	0.767-1.336	0.929	-	-	-
Female	1.000			1.000		
Male	1.208	1.008-1.448	0.041	1.000	0.887-1.327	0.427
Rural and Urban	1.200	1.000-1.440	0.041	1.005	0.007-1.527	0.427
Comp rural	1.000			-		
Counties	0.826	0.465-1.465	0.512	-	_	-
Urban	0.998	0.540-1.846	0.996	-	-	-
Marital Status						
Married	1.000			-		
Divorced/ Separated	1.263	0.974-1.638	0.079	1.243	0.948-1.631	0.115
Unmarried/Single	1.208	0.965-1.513	0.100	1.164	0.907-1.496	0.233
Widowed	1.283	0.992-1.660	0.058	1.075	0.803-1.439	0.629
Unknown	1.184	0.827-1.696	0.356	0.917	0.627-1.340	0.653
insurance Recode						
Insured	1.000			1.000		
Any Medicaid	1.061	0.854-1.319	0.594	0.971	0.766-1.231	0.807
Uninsured	1.653	1.178-2.321	0.004	1.574	1.075-2.302	0.020
Primary Site – labeled						
C15.0-Cervical esophagus	1.000	0.010.0.000	0.400	1.000	0.000 4.700	0.010
C15.1-Thoracic esophagus	1.481	0.916-2.396	0.109	1.029	0.622-1.702	0.913
C15.3-Upper third esophagus	1.205	0.772-1.881	0.412	1.185	0.750-1.875	0.467
C15.4-Middle third esophagus	1.350 1.652	0.905-2.013	0.141 0.015	1.358 1.461	0.893-2.063	0.152
C15.5-Lower third esophagus C15.8/9-Overlappinglesion/NOS	1.652	1.104–2.471 1.228–2.915	0.015	1.401	0.955-2.235 0.892-2.202	0.080 0.143
Grade	1.692	1.226-2.915	0.004	1.401	0.892-2.202	0.145
Grade I	1.000			_		
Grade II	1.156	0.694-1.924	0.578	_	_	_
Grade III	1.389	0.835-2.311	0.206	-	_	-
Grade IV	0.823	0.322-2.105	0.684	-	_	-
Unknown	1.305	0.773-2.203	0.319	-	-	-
AJCC Stage						
IB	1.000			1.000		
IIA	1.123	0.775-1.625	0.540	0.873	0.479-1.591	0.657
IIC	2.221	1.208-4.084	0.010	1.379	0.410-4.637	0.604
V	2.191	1.809-2.653	< 0.001	1.213	0.906-1.626	0.195
Unknown	1.969	1.478-2.624	< 0.001	0.765	0.425-1.375	0.370
Г Stage						
Г1а	1.000			1.000		
Г1Ь	0.442	0.301-0.648	< 0.001	0.554	0.311-0.989	0.045
Γ1NOS	1.217	0.960-1.542	0.105	1.088	0.583-2.029	0.791
N Stage	4 64 -			4 64 -		
N1	1.000	0.001 1.11	0.550	1.000	0.000 0.000	0.045
N2	1.089	0.821-1.444	0.556	1.309	0.830-2.066	0.247
N3	1.632	1.279-2.083	< 0.001	1.376	0.839-2.256	0.206
NX M Stage	1.543	0.920-2.589	0.100	0.894	0.326-2.449	0.827
M Stage M0	1.000			1.000		
M0 M1	1.922	1.611-2.294	<0.001	1.000 NA	NA	NA
Summary stage	1.322	1.011-2.234	<0.001	11/1	1 1/2 1	INЛ
Localized	1.000			1.000		
Regional	0.981	0.741-1.299	0.894	1.364	1.040-1.789	0.025
Distant	0.463	0.345-0.621	< 0.001	NA	NA	NA
Radiation with surgery	2.105			•		
None	1.000			1.000		
Before surgery	0.398	0.262-0.606	< 0.001	5.282	2.579- 10.819	< 0.00
After surgery	0.427	0.276-0.661	< 0.001	1.029	0.607-1.745	0.916
Before and after surgery	0.000	0	0.989	0.000	0	0.992
Surg Prim Site						
None	1.000			1.000		
Endoscopic therapy	1.481	0.369-5.945	0.579	1.393	0.336-5.769	0.647
Partial esophagectomy	0.205	0.066-0.637	0.006	0.098	0.026-0.375	< 0.00
Total esophagectomy	0.173	0.055-0.537	0.002	0.170	0.047-0.615	0.007
Esophagectomy, NOS	0.273	0.166-0.450	< 0.001	0.196	0.091-0.422	< 0.00
Radiation recode						
	1.000			1.000		
Radiation recode	1.000 1.127	0.466-2,729	0.790	1.000 0.947	0.359-2.495	0.912

Table 2 (continued)

Variable	Univariate analysis		р-	Multiva	Multivariate analysis	
	HR	95%CI	value	HR	95%CI	
						value
Chemotherapy						
Yes	1.000			1.000		
None/Unknown	2.786	2.340-3.317	< 0.001	3.020	2.432-3.751	< 0.001
CS extension						
100 mm	1.000			1.000		
110–170 mm	0.584	0.421-0.811	0.001	1.021	0.591-1.764	0.940
210-300 mm	1.127	0.862-1.474	0.381	0.866	0.439-1.710	0.679
No. of malignant tumors						
1	1.000			1.000		
2	0.762	0.620-0.935	< 0.001	0.898	0.723-1.117	0.335
3	0.734	0.509-1.059	0.098	0.832	0.559-1.239	0.365
No. of benign tumors						
0	1.000			-		
1	0.302	0.042-2.150	0.232	-	-	-

LNM: lymph node metastases; NOS: Not specific; HR: hazard ratio.

Table 3

The validation of the nomogram versus the 7th AJCC staging system by C-index, NRI, and IDI

	Training cohort			Validation cohort		
Index	Estimate	95%CI	P- value	Estimate	95%CI	P- value
NRI versus AJCC Staging system						
For 1-year OS	0.313	0.182-0.408	< 0.001	0.364	0.129-0.526	< 0.001
For 3-year OS	0.483	0.198-0.776	< 0.001	0.325	0.017-0.557	0.040
IDI versus AJCC Staging system						
For 1-year OS	0.132	0.085-0.184	< 0.001	0.171	0.078-0.257	< 0.001
For 3-year OS	0.110	0.038-0.204	< 0.001	0.161	0.042-0.275	< 0.001
C-index						
Nomogram	0.749	0.723-0.774	< 0.001	0.751	0.712-0.790	< 0.001
AJCC Staging system	0.640	0.522-0.671		0.638	0.471-0.805	

positive despite the unfavorable OS [15]. We developed and validated a nomogram that integrates various variables to predict the risk factors related to 1- and 3-year OS for T1 ESCC patients who had positive lymph nodes. NRI, IDI and ROC curve analyses indicated the nomogram showed possessed favorable discrimination, calibration, and clinical usage.

The nomograms that have been developed for EC patients mainly focus on the whole stage and type. Thus far, there are only five papers for early EC patients, and none of the nomograms targeted early ESCC with lymph node metastases [16-20]. Li et al. have published a study on early EC patients who are nonoperative [17]. In this study, the OS of patients who had undergone chemoradiotherapy (CRT) was initially compared with that of patients who had undergone radiotherapy (RT). In this study, subgroup analysis was introduced to make the comparison more reliable, and the identified prognostic factors to build the nomogram were evaluated. Eight variables were fitted into the model, in which the type of therapy was recognized as the most significant contributor to the prognosis, followed by histology, T stage, race, N stage, age, sex, and site. The discrimination of the nomogram model was poor. The C-index value was 0.595 in the training dataset and 0.587 in the validation dataset, and the AUC values of the 3-year survival rate were 0.642 and 0.642 in the training and validation cohorts, respectively. Moreover, the accuracy and clinical value for the nomogram were not discussed. In the present study, the discrimination and calibration as well as the accuracy and clinical utility of the nomogram were analyzed, and compared with the 7th AJCC staging system by applying C-index, calibration plots, NRI, IDI, and DCA. Our nomogram C-index was 0.750 vs. 0.645 for the 7th AJCC. From the calibration plots, good calibration was observed. As indicated by the positive NRI and IDI, the present nomogram is more accurate in predicting OS than the 7th AJCC system. Moreover, based on DCA, the nomogram built in this study achieved better clinical benefits than the conventional staging system. In the present nomogram, in addition to the pathological features (e.g., summary stage, primary site) which are included in the 7th AJCC evaluated system, the clinical treatments such as radiation, chemotherapy, and surgery, which influence the prognosis significantly, and demographic factors were entered into the nomogram. Overall, the present nomogram can be more comprehensive and personalized to evaluate the prognosis of T1 ESCC patients with lymph node metastases.

For the most significant factor to predict the OS for the nomogram, radiation sequence with surgery was considered for patients who underwent radiation before and/or after surgery/Endoscopic therapy (ET). ET or Surgery followed by Radiotherapy (RT) have been recommended for T1 ESCC patients at risk of lymph node invasion [21] In this study, patients who underwent radiation after ET or surgery indeed showed prolonged OS than those who had radiation before ET or surgery, in agreement with existing findings [22,23]. However, Zheng wang. et al. demonstrated that neoadjuvant therapy with surgery would be the current optimal treatment for thoracic esophageal cancer (EC) patients with the potential risk of metastatic lymph node [24]. Regardless of the sequence with surgery/ET, patients with chemotherapy or radiation therapy exhibited better OS performance than those without such a therapy. In this study, esophagectomy had better performance than endoscopic therapies (e.g., photodynamic therapy, electrocautery, cryosurgery, and laser esophagectomy), which was similar to findings in other studies [25-27]. However, it should be noted that as adverse events, the mortality rate and morbidity rate accompanied with esophagectomy is about 10% and 50%, respectively. The 5-year survival rate after receiving treatment is stable at 20%. [28]. For the summary stage, in agreement with the findings of Kim et al. [29], patients with localized ESCC outperformed those with regional and distanced ones. Localized patients would have fewer lymph node metastases than the other two types would, which might contribute to this result.

Uninsured status, as a financial factor, was identified as a risk factor for this group of patients. This conclusion is consistent with that of Grant et al. [30] and Saraiya et al. [31], who found that the patients




Fig. 2. ROC Curves of nomogram and the 7th AJCC staging system to predict 1-year and 3-year OS for T1 lymph node-positive ESCC patients in the training cohort (A-B) and in the validation cohort (C-D). The blue curve was for nomogram and the red one was for the AJCC staging system. The larger the AUC, the better was the discrimination of the model.

without insurance experienced unfavorable cancer outcomes. This can be explained by several reasons. First, an uninsured population is less likely to undergo cancer screening than an insured one [32]. Second, an uninsured population is more prone to have poor financial conditions and thus have reduced access to health services [33]. Lastly, an uninsured group tends to have poorer living habits (e.g., smoking, alcohol abuse, and poor nutrition), which are risk factors for ESCC [34]. The different effects of insured and uninsured care on the prognosis of ESCC observed here indicate the need for health care reform.

In this study, surprisingly, T1a patients exhibited worse outcomes than T1b patients. Normally, patients in the T1b stage have worse prognoses than those in the T1a stage [35-38]. However, several studies have reported that the Tn stages have better outcomes than the Tn-1 stage (e.g., T2 over T1 [26,39], T3/4 over T1/T2 [40,41] as well as, T4 over T3 [42]), and is primarily associated with lymph node invasion. The prognosis of advanced cancers (Tn) with a few positive nodes may be similar to or better than that of less advanced cancers (Tn-1) with more positive nodes. Moreover, as compared to T1a patients (except for T1a involving the muscularis mucosa), T1b patients with positive lymph nodes are more likely to receive adjuvant therapy after surgery, leading to better clinical results [43]. It is noteworthy that the prognosis of patients cannot be evaluated merely based on the T stage.

There are several limitations of this study. First, this cohort was based on the American population, which may not fit the population of other countries and limit the prediction ability of the nomogram. Furthermore, some demographic factors related to ESCC prognosis (e.g., smoking, drinking and dietary habits) were not considered in this nomogram. Third, this study lacks external validation. For subsequent research, more data regarding valuable prognosis risk characteristics should be included, and an external validation should be conducted to testify the prediction ability of the nomogram.

Conclusion

Eight variables, comprising insurance, T stage, summary stage, primary site, radiation code, chemotherapy, surgery, and radiation se-




Fig. 3. Calibration curves for predicting 1-year and 3-year OS for T1 lymph node-positive ESCC patients in the training cohort (A-B) and in the validation cohort (C-D). The red dots represent the accuracy of the nomogram prediction. The closer the red line to the gray line, the greater is the accuracy of the nomogram.

quence with surgery, were integrated into a nomogram. Among these OS-related factors, the radiation sequence with surgery was identified as the most significant predictive variable, followed by the type of surgery and chemotherapy. For the T stage, patients at T1a stage showed more disappointing performance, based on OS, as compared to patients at T1b stage. The present nomogram with internal validation showed its advantage in predicting 1-year and 3-year OS compared to the 7th AJCC staging system and may provide more optimal performance for the prediction of survival time and the provision of suitable treatment recommendations for patients.

Author contribution

Jia Yu: Conceptualization, Methodology, Software, Validation, Resources, Formal analysis, Data Curation, Writing - Original Draft. Wenyu Hu: Resources, Validation, Data Curation. Nan Yao: Resources, Data Curation. Mengzi Sun: Resources, Data Curation. Xiaotong Li: Data Curation.

Ling Wang: Data Curation.

- Yixue Yang: Data Curation.
- Bo Li: Writing Review & Editing, Supervision.

Funding

There was no funding from the public, commercial, or not-for-profit sectors for the present study.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors thank Jianjun Zhang and Yutong Sui for assistance with data analysis and comments that improved the manuscript substantially.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.tranon.2021.101127.




Fig. 4. Decision curve analysis (DCA) for the nomogram model and the AJCC staging system in the training cohort (A-B) and validation cohort (C-D) for predicting 1- and 3-year OS. The red solid lines represent the DCA of the nomogram, and the green dashed lines represent the AJCC staging system. The turquoise dashed line assumes that all patients were alive, while the purple dashed line assumes that all patients were dead.

References

- F Bray, J Ferlay, I Soerjomataram, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 68 (2018) 394–424, doi:10.3322/caac.21492.
- [2] HG Coleman, SH Xie, J. Lagergren, The epidemiology of esophageal adenocarcinoma, Gastroenterology 154 (2018) 390–405, doi:10.1053/j.gastro.
- [3] W Huang, B Li, H Gong, et al., Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases. Radiotherapy and oncology, J. Eur. Soc. Therap. Radiol. Oncol. 95 (2010) 229–233, doi:10.1016/j.radonc.2010.01.006.
- [4] Y Akutsu, K Murakami, M Kano, et al., The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma, Esophagus: Off. J. Jpn. Esophageal Soc. 15 (2018) 103–108, doi:10.1007/s10388-018-0604-1.
- [5] T Aikou, Y Kitagawa, M Kitajima, et al., Sentinel lymph node mapping with GI cancer, Cancer Metastasis Rev. 25 (2006) 269–277, doi:10.1007/s10555-006-8507-3.
- [6] JW. Cho, The role of endosonography in the staging of gastrointestinal cancers, Clin. Endosc. 48 (2015) 297–301, doi:10.5946/ce.2015.48.4.297.
- [7] SG Wu, JY Sun, LC Yang, et al., Prognosis of patients with esophageal squamous cell carcinoma after esophagectomy using the log odds of positive lymph nodes, Oncotarget 6 (2015) 36911–36922, doi:10.18632/oncotarget.5366.

- [8] S Blandin, PA Crosbie, H Balata, et al., Progress and prospects of early detection in lung cancer, Open Biol. 33 (2017) 121–128, doi:10.1098/rsob.170070.
- [9] AB Joyner, CD. Runowicz, Ovarian cancer screening and early detection, Womens Health 5 (2009) 693–699, doi:10.2217/whe.09.65.
- [10] S Malik, G Sharma, MR Sanaka, et al., Role of endoscopic therapy in early esophageal cancer, World J. Gastroenterol. 24 (2018) 3965–3973, doi:10.3748/wjg.v24.i35.3965.
- [11] NK. Altorki, Three-field lymphadenectomy for esophageal cancer, Chest Surg. Clin. N. Am. 10 (2000) 553–560, doi:10.1016/j.jss.2020.05.057.
- [12] VP Balachandran, M Gonen, JJ Smith, et al., Nomograms in oncology: more than meets the eye, Lancet Oncol. 16 (2015) 173–180, doi:10.1016/s1470-2045(14)71116-7.
- GS. Collins, How can I validate a nomogram? Show me the model, Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol. 26 (2015) 1034–1035, doi:10.1093/annonc/mdv069.
- [14] SY. Park, Nomogram: An analogue tool to deliver digital knowledge, J. Thorac. Cardiovasc. Surg. 155 (2018) 1793, doi:10.1016/j.jtcvs.2017.12.107.
- [15] DC Codipilly, Y Qin, SM Dawsey, et al., Screening for esophageal squamous cell carcinoma: recent advances, Gastrointest. Endosc. 88 (2018) 413–426, doi:10.1016/j.gie.2018.04.2352.
- [16] XF Duan, P Tang, XB Shang, et al., The prevalence of lymph node metastasis for pathological T1 esophageal cancer: a retrospective study of 143 cases, Surg. Oncol. 27 (2018) 1–6, doi:10.1016/j.suronc.2017.11.002.
- [17] J Li, Y Jia, Y Cheng, et al., Chemoradiotherapy vs radiotherapy for nonoperative

early stage esophageal cancer: a seer data analysis, Cancer Med. 9 (2020) 5025-5034, doi:10.1002/cam4.3132.

- [18] M Shi, JW Tang, ZR. Cao, Nomograms for predicting survival in earlyonset esophageal cancer, Expert Rev. Gastroenterol. Hepatol. 15 (2020) 1–10, doi:10.1080/17474124.2021.1842194.
- [19] D Tian, KY Jiang, H Huang, et al., Clinical nomogram for lymph node metastasis in pathological T1 esophageal squamous cell carcinoma: a multicenter retrospective study, Ann. Transl. Med. 8 (2020) 292–300, doi:10.21037/atm.2020.02.185.
- [20] LY Xue, XM Qin, Y Liu, et al., Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma, World J. Gastroenterol. 24 (2018) 5154–5166, doi:10.3748/wjg.v24.i45.5154.
- [21] A Bhatt, S Kamath, SC Murthy, et al., Multidisciplinary evaluation and management of early stage esophageal cancer, Surg. Oncol. Clin. N. Am. 29 (2020) 613–630, doi:10.1016/j.soc.2020.06.011.
- [22] X Lyu, J Huang, Y Mao, et al., Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? J. Surg. Oncol. 110 (2014) 864–868, doi:10.1002/jso.23716.
- [23] RQ Qin, YS Wen, WP Wang, et al., The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis, Med. Oncol. 31 (2016) 1–10, doi:10.1007/s12032-016-0746-8.
- [24] Z Wang, Y Mao, S Gao, et al., Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy, Ann. N. Y. Acad. Sci. 148 (2020) 20–29. doi:10.1111/nvas.14427.
- [25] M Stahl, C Mariette, K Haustermans, et al., Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 24 (2013) 51–56, doi:10.1093/annonc/mdt342.
- [26] MK Ferguson, AD Celauro, V. Prachand, Prediction of major pulmonary complications after esophagectomy, Ann. Thorac. Surg. 91 (2011) 1494–1500, doi:10.1016/j.athoracsur.2010.12.036.
- [27] B Li, H Chen, J Xiang, et al., Prevalence of lymph node metastases in superficial esophageal squamous cell carcinoma, J. Thorac. Cardiovasc. Surg. 146 (2013) 1198– 1203, doi:10.1016/j.jtcvs.2013.07.006.
- [28] PA Linden, DJ. Sugarbaker, Section V: techniques of esophageal resection, Semin. Thorac. Cardiovasc. Surg. 15 (2003) 197–209, doi:10.1016/S1043-0679(03)00021-2.
- [29] A Kim, P Ashman, M Ward-Peterson, et al., Racial disparities in cancer-related survival in patients with squamous cell carcinoma of the esophagus in the US between 1973 and 2013, PLoS One 12 (2017) 1–11, doi:10.1371/journal.pone.0183782.
- [30] SR Grant, GV Walker, BA Guadagnolo, et al., A brighter future? The impact of insurance and socioeconomic status on cancer outcomes in the USA: a review, Future Oncol. 12 (2016) 1507–1515, doi:10.2217/fon-2015-0028.

- [31] M Saraiya, LC Cheung, A Soman, et al., Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017, Am. J. Obstet. Gynecol. 1 (2020) 11–32, doi:10.1016/j.ajog.2020.10.001.
- [32] G Zhao, CA Okoro, J Li, et al., Health insurance status and clinical cancer screenings among U.S. adults, Am. J. Prev. Med. 54 (2018) 11–19, doi:10.1016/j.amepre.2017.08.024.
- [33] CG Guo, DB Zhao, Q Liu, et al., A nomogram to predict lymph node metastasis in patients with early gastric cancer, Oncotarget 8 (2017) 12203–12210, doi:10.18632/oncotarget.14660.
- [34] ML Rohlfing, AC Mays, S Isom, et al., Insurance status as a predictor of mortality in patients undergoing head and neck cancer surgery, Laryngoscope 127 (2017) 2784– 2789, doi:10.1002/lary.26713.
- [35] CG Guo, DB Zhao, Q Liu, et al., A nomogram to predict lymph node metastasis in patients with early gastric cancer, Oncotarget 8 (2017) 12203–12210, doi:10.18632/oncotarget.14660.
- [36] CG Guo, YJ Chen, H Ren, et al., A nomogram for predicting the likelihood of lymph node metastasis in early gastric signet ring cell carcinoma: A single center retrospective analysis with external validation, Medicine 95 (2016) 1–6, doi:10.1097/MD.00000000005393.
- [37] H Jin, Y Feng, K Guo, et al., Prognostic nomograms for predicting overall survival and cancer-specific survival of patients with early onset colon adenocarcinoma, Front. Oncol. 10 (2020) 1–11, doi:10.3389/fonc.2020.595354.
- [38] J Mu, Z Jia, W Yao, et al., Predicting lymph node metastasis in early gastric cancer patients: development and validation of a model, Future Oncol. 15 (2019) 3609– 3617, doi:10.2217/fon-2019-0377.
- [39] XY Yin, T Pang, Y Liu, et al., Development and validation of a nomogram for preoperative prediction of lymph node metastasis in early gastric cancer, World J. Surg. Oncol. 18 (2020) 1–10, doi:10.1186/s12957-019-1778-2.
- [40] J Li, Y Jia, Y Cheng, et al., Chemoradiotherapy vs radiotherapy for nonoperative early stage esophageal cancer: a seer data analysis, Cancer Med. 9 (2020) 5025– 5034, doi:10.1002/cam4.3132.
- [41] Y Xu, G Xu, H Wu, et al., The nomogram for early death in patients with bone and soft tissue tumors, J. Cancer 11 (2020) 5359–5370, doi:10.7150/jca.46152.
- [42] J Fu, L Wu, M Jiang, et al., Clinical nomogram for predicting survival outcomes in early mucinous breast cancer, PLoS One 11 (2016) 1–16, doi:10.1371/journal.pone.0164921.
- [43] TY Kam, M Kountouri, A Roth, et al., Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: a critical review, Crit. Rev. Oncol. Hematol. 124 (2018) 61–65, doi:10.1016/j.critrevonc.2018.02.011.